PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT3275838

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

CONVEYING PARTY DATA

Name	Execution Date
NANOTHERAPEUTICS, INC.	02/27/2015

RECEIVING PARTY DATA

Name:	WHITE OAK GLOBAL ADVISORS, LLC
Street Address:	3 EMBARCADERO CENTER, SUITE 550
City:	SAN FRANCISCO
State/Country:	CALIFORNIA
Postal Code:	94111

PROPERTY NUMBERS Total: 96

Property Type	Number
Patent Number:	6406745
Patent Number:	7063748
PCT Number:	US0301065
PCT Number:	US0300040
PCT Number:	US0311488
Patent Number:	8501232
PCT Number:	US0506579
Patent Number:	7829105
Patent Number:	7846459
PCT Number:	US0625918
Patent Number:	8074906
PCT Number:	US0810318
Patent Number:	8377479
Application Number:	13741915
PCT Number:	US0954130
Patent Number:	7705135
Patent Number:	7691986
PCT Number:	US1999011133
PCT Number:	US9910335
Patent Number:	5929051

PATENT REEL: 035236 FRAME: 0932

503229220

Property Type	Number
Patent Number:	7022683
Patent Number:	6274548
PCT Number:	US0205974
PCT Number:	US0416146
Patent Number:	6777000
Patent Number:	7494669
PCT Number:	US0725487
PCT Number:	US0517121
PCT Number:	US2005035935
Patent Number:	7488736
Patent Number:	7407966
Patent Number:	7576211
Patent Number:	7598265
Patent Number:	7982040
PCT Number:	US0966589
Patent Number:	8114894
PCT Number:	US0412856
Application Number:	12387226
PCT Number:	US0317709
Patent Number:	7317001
Patent Number:	5247997
Patent Number:	5539087
Patent Number:	6720305
Patent Number:	7273714
PCT Number:	US2005010152
Patent Number:	7605137
PCT Number:	US2005033641
Patent Number:	7405317
PCT Number:	US2004015547
Patent Number:	6855695
Patent Number:	8026095
PCT Number:	US0023242
Patent Number:	6962696
Patent Number:	7452531
PCT Number:	US9809803
Patent Number:	5869676
PCT Number:	US9809750
Patent Number:	5767134

Property Type	Number
PCT Number:	US0132085
Patent Number:	6458816
Patent Number:	6005097
Application Number:	60352322
Application Number:	61089568
Application Number:	60571582
Application Number:	60738084
Application Number:	61119538
Application Number:	60465757
Application Number:	60408596
Application Number:	60469803
Application Number:	61372184
Application Number:	60660738
Application Number:	60663454
Application Number:	60157500
Application Number:	60157581
Application Number:	60157637
Application Number:	60240529
Application Number:	60931528
Application Number:	61128975
Application Number:	60549950
Application Number:	60551981
Application Number:	60549598
Application Number:	60660357
Application Number:	60660356
Application Number:	60781866
Application Number:	60906896
Application Number:	60611623
Application Number:	60615419
Application Number:	60616500
Application Number:	60670308
Application Number:	60157620
Application Number:	61150928
Application Number:	60352259
Application Number:	61948085
Application Number:	61980370
PCT Number:	US1997009486
Application Number:	13827667

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (415) 278-9024

Email: landwebe@chapman.com
Correspondent Name: JOSEPH LANDWEBER

Address Line 1:595 MARKET STREET, 26TH FLOORAddress Line 4:SAN FRANCISCO, CALIFORNIA 94105

NAME OF SUBMITTER:	JOSEPH LANDWEBER	
SIGNATURE:	/Joseph Landweber/	
DATE SIGNED:	03/20/2015	

Total Attachments: 22 source=3766959#page1.tif source=3766959#page2.tif source=3766959#page3.tif source=3766959#page4.tif source=3766959#page5.tif source=3766959#page6.tif source=3766959#page7.tif source=3766959#page8.tif source=3766959#page9.tif source=3766959#page10.tif source=3766959#page11.tif source=3766959#page12.tif source=3766959#page13.tif source=3766959#page14.tif source=3766959#page15.tif source=3766959#page16.tif source=3766959#page17.tif source=3766959#page18.tif source=3766959#page19.tif source=3766959#page20.tif source=3766959#page21.tif source=3766959#page22.tif

RECORDATION FORM COVER SHEET PATENTS ONLY	
To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.	
1. Name of conveying party(ies)	2. Name and address of receiving party(ies)
	Name: White Oak Global Advisors, LLC
Nanotherapeutics, Inc.	Internal Address:
Additional name(s) of conveying party(ies) attached? Yes No 3. Nature of conveyance/Execution Date(s): Execution Date(s) February 27, 2015 Assignment Merger Security Agreement Change of Name Joint Research Agreement Government Interest Assignment Executive Order 9424, Confirmatory License Other 4. Application or patent number(s): This A. Patent Application No.(s)	Street Address: 3 Embarcadero Center, Suite 550 City: San Francisco State: California Country: USA Zip: 94111 Additional name(s) & address(es) attached? Yes No document is being filed together with a new application. B. Patent No.(s)
See Schedule A attached hereto Additional numbers at	See Schedule A attached hereto tached? X Yes No
5. Name and address to whom correspondence concerning document should be mailed:	6. Total number of applications and patents involved: 96
Name: Joseph Landweber	7. Total fee (37 CFR 1.21(h) & 3.41) \$0.00
Internal Address: Street Address: Chapman and Cutler LLP 595 Market Street, 26th Floor	Authorized to be charged to deposit account Enclosed None required (government interest not affecting title)
	8. Payment Information
City: San Francisco	
State: California Zip: 94105	
Phone Number: (415) 278-9024	Deposit Account Number
Docket Number:	Authorized User Name
Email Address: landwebe@chapman.com	1
9. Signature: Signature Toseph Landwebe Name of Person Signing Documents to be recorded (including cover she	Total number of pages including cover sheet, attachments, and documents: 22 et) should be faxed to (571) 273-0140, or mailed to: of the USPTO, P.O.Box 1450, Alexandria, V.A. 22313-1450

Schedule A to Patent Cover Sheet

1. Patent #:6406745
2. Patent #:7063748
3. PCT #:US0301065
4. PCT #:US0300040
5. PCT #:US0311488
6. Patent #:8501232
7. PCT #:US0506579
8. Patent #:7829105
9. Patent #:7846459
10. PCT #:US0625918
11. Patent #:8074906
12. PCT #:US0810318
13. Patent #:8377479
14. Application #:13741915
15. PCT #:US0954130
16. Patent #:7705135
17. Patent #:7691986
18. PCT #:US1999011133
19. PCT #:US9910335
20. Patent #:5929051
21. Patent #:7022683
22. Patent #:6274548
23. PCT #:US0205974
24. PCT #:US0416146
25. Patent #:6777000
26. Patent #:7494669
27. PCT #:US0725487
28. PCT #:US0517121
29. PCT #:US2005035935
30. Patent #:7488736
31. Patent #:7407966
32. Patent #:7576211
33. Patent #:7598265
34. Patent #:7982040
35. PCT #:US0966589
36. Patent #:8114894
37. PCT #:US0412856

38. Application #:12387226
39. PCT #:US0317709
40. Patent #:7317001
41. Patent #:5247997
42. Patent #:5539087
43. Patent #:6720305
44. Patent #:7273714
45. PCT #:US2005010152
46. Patent #:7605137
47. PCT #:US2005033641
48. Patent #:7405317
49. PCT #:US2004015547
50. Patent #:6855695
51. Patent #:8026095
52. PCT #:US0023242
53. Patent #:6962696
54. Patent #:7452531
55. PCT #:US9809803
56. Patent #:5869676
57. PCT #:US9809750
58. Patent #:5767134
59. PCT #:US0132085
60. Patent #:6458816
61. Patent #:6005097
62. Application #:60352322
63. Application #:61089568
64. Application #:60571582
65. Application #:60738084
66. Application #:61119538 67. Application #:60465757
68. Application #:60408596
69. Application #:60469803
70. Application #:61372184
71. Application #:60660738
71. Application #:60663454
73. Application #:60157500
74. Application #:60157581
75. Application #:60157637

	-
76. Application #:60240529	
77. Application #:60931528	
78. Application #:61128975	
79. Application #:60549950	
80. Application #:60551981	
81. Application #:60549598	
82. Application #:60660357	
83. Application #:60660356	
84. Application #:60781866	
85. Application #:60906896	
86. Application #:60611623	
87. Application #:60615419	
88. Application #:60616500	
89. Application #:60670308	
90. Application #:60157620	
91. Application #:61150928	
92. Application #:60352259	
93. Application #:61948085	
94. Application #:61980370	
95. PCT #:US1997009486	
96. Application #:13827667	

PATENT SECURITY AGREEMENT

This PATENT SECURITY AGREEMENT (as amended, supplemented and/or otherwise modified from time to time, this "Agreement"), dated as of February 27, 2015, is between NANOTHERAPEUTICS, INC., a Delaware corporation (the "Grantor"), and WHITE OAK GLOBAL ADVISORS, LLC, a Delaware limited liability company ("Administrative Agent"), as Administrative Agent for the benefit of the Lenders party to that certain Loan Agreement (as hereinafter defined).

RECITALS

- A. Grantor has entered into or is in the process of entering into that certain Loan and Security Agreement, dated as of February 27, 2015 (as amended, supplemented and/or otherwise modified from time to time, the "Loan Agreement"), among Grantor and Nano ADM, LLC, a Delaware limited liability company as Borrowers, the entities from time to time party thereto as guarantors, the several entities from time to time party thereto as lenders (collectively, "Lenders"), and Administrative Agent, pursuant to which Lenders have agreed, subject to certain terms and conditions, to extend various financial accommodations to Grantor.
- B. Pursuant to the Loan Agreement, Grantor grants, pledges and assigns to Administrative Agent for the benefit of the Lenders a security interest in, among other assets, the Intellectual Property (as defined in the Loan Agreement) owned by Grantor.
 - C. Grantor has duly authorized the execution, delivery and performance of this Agreement.

NOW THEREFORE, for good and valuable consideration (the receipt and sufficiency of which are hereby acknowledged), and in order to induce Lenders to extend credit to Grantor pursuant to the Loan Agreement, Grantor agrees, for the benefit of Administrative Agent, as follows:

- Section 1. Definitions. Unless the context otherwise requires, each capitalized term used but not otherwise defined herein has the meaning ascribed thereto in the Loan Agreement.
- Section 2. Grant of Security Interest. For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, to secure the prompt payment and performance when due of all of the Obligations, Grantor hereby grants, pledges and assigns a security interest to Administrative Agent in and to, all of the following, whether now owned or hereafter acquired (collectively, the "Patent Collateral"):
 - (a) all letters patent of the United States or any other country, all registrations and recordings thereof, and all applications for letters patent of the United States or any other country, including registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State or Territory thereof, or any other country, including without limitation, those patents and patent applications listed on **Schedule A** attached hereto (all of the foregoing are sometimes hereinafter individually and/or collectively referred to as the "Patents");

3739227 3608304

- (b) subject to the terms of the Loan Agreement, all rights under or interest in any patent license agreements with any other party, if any, whether Grantor is a licensee or licensor under any such license agreement, except to the extent where such grant, pledge or assignment is a breach or causes a modification to, or would breach or cause a modification to, with notice, passage of time or both, the terms and conditions of such patent license agreement (all of the foregoing are hereinafter referred to collectively as the "Patent Licenses"); and
- (c) all income, royalties, damages, payments and proceeds at any time due or payable to Grantor under and with respect to any of the foregoing, including, without limitation, all of Grantor's rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation, dilution, violation or other impairment thereof, subject to the terms of any patent license or other similar agreement, as the case may be.
- Section 3. New Patents. If, before the Obligations shall have been paid in full, Grantor shall obtain rights to any new Patents or Patent Licenses, the provisions of Section 2 shall automatically apply thereto. Grantor shall promptly update Schedule A attached hereto as necessary, but no more frequently than once per fiscal quarter, and provide written notice to Administrative Agent of such updates on a fiscal quarterly basis. Grantor authorizes Administrative Agent to modify this Agreement by amending Schedule A attached hereto to reflect such updates.
- opposition proceedings, interferences, cancellation proceedings, or lawsuits in its own name to enforce or protect the Patents, provided that during the continuance of an Event of Default, Grantor shall seek the prior written consent of Administrative Agent, which will not be unreasonably withheld or delayed, in which event Administrative Agent may, if necessary, be joined or named as a nominal party to such suit if Administrative Agent shall have been satisfied that it is not thereby incurring or has been adequately indemnified against any risk of liability because of such joinder. Grantor hereby agrees that, notwithstanding anything to the contrary contained herein or in the Loan Documents, as between Grantor and Administrative Agent, Grantor shall assume full and complete responsibility for the prosecution, defense, enforcement or any other necessary or desirable actions in connection with all or any of the Patent Collateral so long as Grantor is the owner of such Patent Collateral. Grantor shall promptly, upon demand, reimburse and indemnify Administrative Agent for all damages, costs, and expenses, including attorneys' fees, incurred by Administrative Agent in the fulfillment of the provisions of this Section 4.
- Section 5. Loan Agreement. This Agreement has been executed and delivered by Grantor for the purpose of registering the security interest of Administrative Agent in the Patent Collateral with the United States Patent and Trademark Office. The security interest granted hereby has been granted as a supplement to, and not in limitation of, the security interest granted to Lenders under the Loan Agreement. The Loan Agreement (and all rights and remedies of Administrative Agent and each Lender thereunder) shall remain in full force and effect in accordance with its terms and is incorporated herein by this reference.
- Section 6. Release of Security Interest. Upon the payment in full of the Obligations or otherwise in accordance with the terms of the Loan Agreement, the Patent Collateral shall be released from the security interest granted hereby and in the Loan Agreement and all obligations of Grantor hereunder shall terminate, all without delivery of any instrument or performance of any act by any party,

and all right, title and interest in and to the Patent Collateral shall revert to Grantor. At the request and expense of Grantor, Administrative Agent shall promptly execute and deliver to Grantor all instruments and other documents as may be reasonably necessary to release the security interest in and to the Patent Collateral that has been granted hereunder.

- Section 7. Acknowledgment. Grantor does hereby further acknowledge and affirm that the rights and remedies of Administrative Agent with respect to the security interest in the Patent Collateral granted hereby are more fully set forth in the Loan Agreement, the terms and provisions of which (including the remedies provided for therein) are incorporated herein by this reference.
- Section 8. Loan Document. This Agreement is a Loan Document executed pursuant to the Loan Agreement and shall (unless otherwise expressly indicated herein) be construed, administered and applied in accordance with the terms and provisions of the Loan Agreement.
- Section 9. Counterparts. This Agreement may be executed in counterparts (and by the different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract.

Section 10. GOVERNING LAW; JURISDICTION; ETC.

- (a) GOVERNING LAW. THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF CALIFORNIA.
- SUBMISSION TO JURISDICTION. EACH OF THE PARTIES HERETO IRREVOCABLY AND (b) UNCONDITIONALLY SUBMITS, FOR ITSELF AND ITS PROPERTY, TO THE NONEXCLUSIVE JURISDICTION OF THE COURTS OF THE STATE OF CALIFORNIA SITTING IN THE CITY AND COUNTY OF SAN FRANCISCO AND OF THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF CALIFORNIA, AND ANY APPELLATE COURT FROM ANY THEREOF, IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT TO WHICH EACH IS A PARTY, OR FOR RECOGNITION OR ENFORCEMENT OF ANY JUDGMENT, AND EACH OF THE PARTIES HERETO IRREVOCABLY AND UNCONDITIONALLY AGREES THAT ALL CLAIMS IN RESPECT OF ANY SUCH ACTION OR PROCEEDING MAY BE HEARD AND DETERMINED IN SUCH STATE COURTS OR, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAWS, IN SUCH FEDERAL COURTS. EACH OF THE PARTIES HERETO AGREES THAT A FINAL JUDGMENT IN ANY SUCH ACTION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY LAW. NOTHING IN THIS AGREEMENT OR IN ANY OTHER LOAN DOCUMENT SHALL AFFECT ANY RIGHT THAT ADMINISTRATIVE AGENT OR ANY LENDER MAY OTHERWISE HAVE TO BRING ANY ACTION OR PROCEEDING RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT AGAINST ANY LOAN PARTY OR ANY OF ITS PROPERTIES IN THE COURTS OF ANY OTHER JURISDICTION.
- (c) Waiver of Venue. Each of the Parties Hereto Irrevocably and unconditionally waives, to the fullest extent permitted by applicable Laws, any objection that it may now or hereafter have to the Laying of Venue of any action or proceeding arising out of or relating to this Agreement or any other Loan Document in any court referred to in subsection (b) of this Section 10. Each of the Parties Hereto Hereby

IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAWS, THE DEFENSE OF AN INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH ACTION OR PROCEEDING IN ANY SUCH COURT.

(d) Service of Process. Each party hereto irrevocably consents to service of Process in the Manner provided for notices in Section 10.02 of the Loan Agreement. Nothing in this Agreement will affect the right of any party hereto to serve process in any other manner permitted by applicable Laws.

Section 11. WAIVER OF RIGHT TO JURY TRIAL.

TO THE EXTENT PERMITTED BY APPLICABLE LAW, EACH OF THE PARTIES HERETO HEREBY WAIVES ITS RIGHT TO A JURY TRIAL OF ANY CLAIM. EACH OF THE PARTIES HERETO REPRESENTS THAT EACH HAS REVIEWED THIS WAIVER AND EACH KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL ON SUCH MATTERS. IN THE EVENT OF LITIGATION, A COPY OF THIS AGREEMENT MAY BE FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT.

IN THE EVENT THAT ANY SUCH ACTION IS COMMENCED OR MAINTAINED IN ANY COURT IN THE STATE OF CALIFORNIA, AND THE WAIVER OF JURY TRIAL SET FORTH ABOVE IS NOT ENFORCEABLE, AND EACH PARTY TO SUCH ACTION DOES NOT SUBSEQUENTLY WAIVE IN AN EFFECTIVE MANNER UNDER CALIFORNIA LAW ITS RIGHT TO A TRIAL BY JURY, THE PARTIES HERETO HEREBY ELECT TO PROCEED AS FOLLOWS:

THE PARTIES AGREE, AND HEREBY AGREE TO ADVISE THE APPLICABLE COURT, THAT THE ADJUDICATION OF ANY SUCH ACTION OR PROCEEDING (AND ALL RELATED CLAIMS) SHALL BE MADE PURSUANT TO CALIFORNIA CODE OF CIVIL PROCEDURE SECTION 638 BY A REFEREE (WHO SHALL BE A SINGLE ACTIVE OR RETIRED JUDGE) WHO SHALL HEAR AND DETERMINE ALL OF THE ISSUES IN SUCH ACTION OR PROCEEDING (WHETHER OF FACT OR OF LAW) AND REPORT A STATEMENT OF DECISION, PROVIDED THAT, AT THE OPTION OF ANY PARTY TO SUCH PROCEEDING, ANY SUCH ISSUES PERTAINING TO A "PROVISIONAL REMEDY" (AS DEFINED IN CALIFORNIA CODE OF CIVIL PROCEDURE SECTION 1281.8), AND ANY NON-JUDICIAL FORECLOSURE OF ANY SECURITY INTERESTS IN REAL OR PERSONAL PROPERTY, THE EXERCISE OF SELF HELP REMEDIES (INCLUDING SET-OFF), THE APPOINTMENT OF A RECEIVER SHALL BE HEARD AND DETERMINED BY THE COURT; AND (B) WITHOUT LIMITING THE GENERALITY OF SECTION 10.04, BORROWERS SHALL BE SOLELY RESPONSIBLE TO PAY ALL FEES AND EXPENSES OF ANY REFEREE APPOINTED IN SUCH ACTION OR PROCEEDING.

THE REFEREE SHALL BE AN ACTIVE OR RETIRED JUDGE OR JUSTICE SELECTED BY MUTUAL WRITTEN AGREEMENT OF THE PARTIES. IF THE PARTIES DO NOT AGREE WITHIN TEN (10) DAYS OF A WRITTEN REQUEST TO DO SO BY ANY PARTY, THEN, UPON REQUEST OF ANY PARTY, THE REFEREE SHALL BE SELECTED BY THE PRESIDING JUDGE OF THE COURT (OR HIS OR HER REPRESENTATIVE). A REQUEST FOR APPOINTMENT OF A REFEREE MAY BE HEARD ON AN EX PARTE OR EXPEDITED BASIS, AND THE PARTIES AGREE THAT IRREPARABLE HARM WOULD RESULT IF EX PARTE RELIEF IS NOT GRANTED.

THE REFEREE SHALL BE REQUIRED TO DETERMINE ALL ISSUES IN ACCORDANCE WITH EXISTING APPLICABLE CASE LAW AND STATUTORY LAW. THE RULES OF EVIDENCE APPLICABLE TO PROCEEDINGS

AT LAW IN THE COURT WILL BE APPLICABLE TO THE REFERENCE PROCEEDING. THE REFEREE SHALL BE EMPOWERED TO ENTER EQUITABLE AS WELL AS LEGAL RELIEF, ENTER EQUITABLE ORDERS THAT WILL BE BINDING ON THE PARTIES AND RULE ON ANY MOTION THAT WOULD BE AUTHORIZED IN A COURT PROCEEDING. THE REFEREE SHALL ISSUE A DECISION AT THE CLOSE OF THE REFERENCE PROCEEDING THAT DISPOSES OF ALL CLAIMS OF THE PARTIES THAT ARE THE SUBJECT OF THE REFERENCE. PURSUANT TO CALIFORNIA CODE OF CIVIL PROCEDURE SECTION 644, SUCH DECISION SHALL BE ENTERED BY THE COURT AS A JUDGMENT OR AN ORDER IN THE SAME MANNER AS IF THE ACTION HAD BEEN TRIED BY THE COURT AND ANY SUCH DECISION WILL BE FINAL, BINDING AND CONCLUSIVE. THE PARTIES RESERVE THE RIGHT TO APPEAL FROM THE FINAL JUDGMENT OR ORDER OR FROM ANY APPEALABLE DECISION OR ORDER ENTERED BY THE REFEREE. THE PARTIES RESERVE THE RIGHT TO FINDINGS OF FACT, CONCLUSIONS OF LAWS, A WRITTEN STATEMENT OF DECISION, AND THE RIGHT TO MOVE FOR A NEW TRIAL OR A DIFFERENT JUDGMENT, WHICH NEW TRIAL, IF GRANTED, IS ALSO TO BE A REFERENCE PROCEEDING UNDER THIS PROVISION.

[SIGNATURE PAGE FOLLOWS.]

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and delivered by their respective officers thereunto duly authorized as of the day and year first written above.

WHITE OAK GLOBAL ADVISORS, LLC, as Administrative Agent	NANOTHERAPEUTICS, INC., as Grantor
By: Sa Jany May May Name: Bullaya U.S. Molee Title: Managing Member	By:

Patent Security Agreement

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and delivered by their respective officers thereunto duly authorized as of the day and year first written above.

WHITE OAK GLOBAL ADVISORS, LLC, as Administrative Agent	NANOTHERAPEUTICS, INC., as Grantor
By: Name:	By: Name: / J. TALION
Title: Managing Member	Title:// /NESMONT LIED

Patent Security Agreement (Nano)

SCHEDULE A TO PATENT SECURITY AGREEMENT

SEE ATTACHED

.NanoCOAT:	NC NC		NanoFUSE:	NF.
NanoBREATH:	NB		NanoQUAD:	NO.
DEAD:	DEAD		NanoBUP:	NBUP
NanoDRY	S		NanoDOX:	NDOX
GELSITE:	GELSITE		Vion:	Vion
PRX 3140:	PRX 3140	,	Cloretazine:	CLOR
Ramoplanin:	RAMO		Tapet:	TAPET
NCL Vaccines:	NOL		Triapine:	TRI
FD4C	FD4C		Provisional:	Provision

				_	_			1		1		т		1		_	_	_	7					- 1						
DEAD	DEAD	DEAD	NB	NB BN	NB NB	NC	NC	N _C	NO	NC NC	NC	NC	NC	NC	NC	NC.	NC .	NC	NC	NO.	NC	NC	NC .	NC	NC	NC	NC	NC	NC	Product/ Tech Codes
08100-0026/00	08100-0019/00	08100-0019/00	08100-0020/01	08100-0020/00	08100-0020/00	08100-0001/01	08100-0001/00	08100-0001/00	08100-0001/00	08100-0001/00256	08100-0001/00	08100-0001/00	08100-0001/00	08100-0001/00	08100-0001/00234	08100-0001/00	08100-0001/00	08100-0001/00195	08100-0001/00	08100-0001/00187	08100-0001/00	08100-0001/00	08100-0001/00	08100-0001/00	08100-0001/00	08100-0001/00	08100-0001/00	08100-0001/01110	08100-0001/00110	CaseSubCase
ORD	PCT	ORD	DIV	PCT	ORD	CON	ORD	PCT	PCT	PCT	PCT	PCT	ORD	PCT	DIV	PCT	CaseType													
Abandoned	Abandoned	Completed	Abandoned	Abandoned	Completed	Issued	Issued	Abandoned	Abandoned	Abandoned	Abandoned	Abandoned	Completed	Abandoned	Abandoned	Pending	Abandoned	Abandoned	Abandoned	Issued	Abandoned	ApplicationStatus								
11/358,348	10/502,022	PCT/US03/00040	11/557,797	90/008,706	PCT/US03/01065	10/095,585	09/588,208	2001/03540	2001/10390	200106993-9	2001135712/14 038525	P351965	No	20015896	515648	2001/012658	1.02002E+12	2001501194	146808	IN/PCT/2001/01224	P0201645	2107718	939600.3	PV2001-4319	808678.8	2376113	PI0011429-4	2005201757	54666/00	Appl. No.
				7153272		7063748	6406745	2001-03540	2001/10390	84848	2250764				515648					208413								2005201757	779427	Patent No.
21-Feb-2006	21-Jul-2004	22-Jan-2003	8-Nov-2006	18-Nov-2004	29-Jan-2003	13-Mar-2002	6-มนท-2000	6-Jun-2000	29-Nov-2001	6-Jun-2000	27-Apr-2005	4-Dec-2001	File Date																	
U.S.	U.S.	PCT	U.S.	U.S.	PCT	U.S.	U.S.	Turkey	South Africa	Singapore	Russia	Pcland	PCT	Norway	New Zealand	Mexico	Korea	Japan	Israel	India	Hungary	Hong Kong	Europe.	Czech Republic	China	Canada	Brazil	Australia	Australia	CountryName
				12-Aug-2008		20-Jun-2006	18-Jun-2002	21-Apr-2004	24-Dec-2002	31-Dec-2003	27-Apr-2005				08-Jun-2004					26-Jul-2007								06-Sep-2007	02-Jun-2005	Issue Date
Inverted cannula for use in reconstituting dry material in syringes	METHOD OF PULSED LASE ASSISTED SURFACE	METHOD OF PULSED LASER ASSISTED SURFACE	APPARATUS FOR COLLECTING AND ANALYZING HUMAN BREATH		METHOD OF COLLECTING AND ANALYZING HUMAN BREATH	METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	
	NANOTHERAPEUTICS, INC.		NANOTHERAPEUTICS, INC.	NANOTHERAPEUTICS, INC.		NANOTHERAPEUTICS, INC.	NANOTHERAPEUTICS, INC.	NANOTHERAPEUTICS, INC.	NANOSPHERE, INC	NANOTHERAPEUTICS, INC.	NANOSPHERE, INC	NANOTHERAPEUTICS, INC.	NANOSPHERE, INC	Assignee																

PATENT

NANOTHERAPEUTICS, INC.	Pharmaceutical compositions compromising aloe pectins and methods for their production and use	27		2000	7 705 135				00100 001600	200
NANOTHERAPEUTICS, INC.	Topical Hydrogel Composition		U.S.	18-Aug-2009		12/542,925	Abandoned	ORD	08100-0042/00	NOOX
NANOTHERAPEUTICS, INC.	Topical Hydrogel Composition		PCT	18-Aug-2009		PCT/US09/54130	Completed	ORD	08100-0042/00	NDOX
NANOTHERAPEUTICS, INC.	Topical Hydrogel Composition		Mexico	17-Feb-2011		MX/a/2011/001812	Abandoned	PCT	08100-0042/00	NDOX
NANOTHERAPEUTICS, INC.	Topical Hydrogel Composition		Korea	16-Mar-2011		10-2011-7006090	Abandoned	PCT	08100-0042/00202	NDOX
NANOTHERAPEUTICS, INC.	Topical Hydrogel Composition		Japan	17-Feb-2011		2011-523925	Abandoned	PCT	08100-0042/00195	NDOX
NANOTHERAPEUTICS, INC.	Topical Hydrogel Composition		India	10-Mar-2011		1046/KOLNP/2011	Abandoned	PCT	08100-0042/00187	NDOX
NANOTHERAPEUTICS, INC.	Topical Hydrogel Composition		Europe	17-Mar-2011		9791606.8	Abandoned	PCT	08100-0042/00155	NDOX
NANOTHERAPEUTICS, INC.	Topical Hydrogel Composition		Canada	17-Feb-2011		2734687	Abandoned	PCT	08100-0042/00131	NDOX
NANOTHERAPEUTICS, INC.	Topical Hydrogel Composition		Australia	10-Mar-2011		2009282659	Abandoned	PCT	08100-0042/00110	NDOX
	Topical Hydrogel Composition		U.S.				Abandoned	ORD.	.08100-0028/00	NDOX
	Topical Hydroget Composition		PCT				Abandoned	ORD	08100-0028/00	NDOX
	Particle Compositions and Methods for Delivery of Poorly Soluble Drugs	1/15/2015	Australia	2-Sep-2008	2008296971	2008296971	Issued	DIV	08100.0035-00110	NBUP
	Particle Compositions and Methods for Delivery of Poorly Soluble Drugs		Australia	15-Dec-2014	2014277657	2014277657	Filed	DIV	08100.0035-01110	NBUP
The state of the s	Compositions and Methods for Delivery of Poorly Soluble Drugs		U.S.	15-Jan-2013		13/741,915	Pending	DIV	08100.0035/01000	NBUP
NANOTHERAPEUTICS, INC.		2/19/2013	U.S.	2-Sep-2008	8,377,479	12/202,881	issued	ORD	08100-0035/00000	NBUP
			PCT	2-Sep-2008		PCT/US08/10318	Completed	ORO.	08100-0035/00	NBUP
		8/9/2013	Mexico	2-Sep-2008	312135	MX/a/2010/002409	issued	PCT	08100-0035/00223	ADUP
NANOTHERAPEUTICS, INC.	Particulate Compositions for Delivery of Poorly Soluble Drugs		Korea	1-Apr-2010	PCT/US2008/010318	10-2010-7007177	Pending	PCT	08100-0035/00202	NBUP
	Particulate Compositions for Delivery of Poorty Soluble Drugs		Japan	2-Mar-2010		2010-522977	Abandoned	PCT	08100-0035/00195	NBUP
	Particulate Compositions for Delivery of Poorly Soluble Drugs		Europe	31-Mar-2010		8829074.7	Pending	PCT	08100-0035/00155	NBUP
	Particulate Compositions for Delivery of Poorty Soluble Drugs		Canada	26-Feb-2010		2,699,172	Pending	PCT	08100-0035/00131	ANBUP
	Particulate Compositions for Delivery of Poorly Soluble Drugs		Australia	24-Feb-2010		2014277657	Pending	PCI	08100-0035/00110	AD BN
NANOTHERAPEUTICS, INC.	Process Milling and Preparing Powders and Compositions Produced Thereby	12/13/2011	U.S.	30-Jun-2006	8,074,906	11/428,064	issued	ORD	08100-0027/00000	ð
	Process Milling and Preparing Powders		PCT	30-Jun-2006		PCT/US06/25918	Completed	ORO	08100-0027/00	š
NANOTHERAPEUTICS, INC.	Process Miling and Preparing Powders and Compositions Produced Thereby		Japan	4-Jan-2008		2008-520325	Lapsed	PG CI	08100-0027/00	Š
NANOTHERAPEUTICS, INC.	Process Miling and Preparing Powders and Compositions Produced Thereby		India	5-Feb-2008		531/KOLNP/2008	Abandoned	PCT	08100-0027/00187	S
NANOTHERAPEUTICS, INC.	Process Milling and Preparing Powders and Compositions Produced Thereby		Hong Kong	30-Jun-2006		8112639.4	Pending	PCT	08100-0027/00178	S
NANOTHERAPEUTICS, INC.	Process Milling and Preparing Powders and Compositions Produced Thereby		Europe	5-Feb-2008		6786179.9	Pending	PCT	08100-0027/00155	S
NANOTHERAPEUTICS, INC.	Process Miling and Preparing Powders and Compositions Produced Thereby	20-May-14	Canada	7-Jan-2008	2,614,409	2614409	Issued	PCT	08100-0027/00131	ã
NANOTHERAPEUTICS, INC.	Methods of Repairing Bone		U.S.	12-Jul-2007		11/776,997	Abandoned	DIV	08100-0022/02	죾
NANOTHERAPEUTICS, INC.	Methods for Preparing Compositions for Repairing Bone	07-Dec-2010	U.S.	12-Jul-2007	7,846,459	11/777,001	issued	υd	08100-0022/01	죾
NANOTHERAPEUTICS, INC.	Compositions for reparing bone	09-Nov-2010	U.S.	2-Mar-2005	7,829,105	11/070,413	Issued	ORD	08100-0022/00	죾
NANOTHERAPEUTICS, INC.	Compositions for repaining bone and methods for preparing and using such compositions		PCI	2-Mar-2005		PCT/US05/06579	Completed	ORD	08100-0022/00	짂
NANOTHERAPEUTICS, INC.	Compositions for reparing bone and methods for preparing and using such compositions	8/6/2012	Korea	1-Sep-2006		10-2006-7017832	Issued	PCT	08100-0022/00202	짂
NANOTHERAPEUTICS, INC.	Compositions for repaining bone and methods for preparing and using such compositions		Japan	4-Sep-2006		2007-501897	Abandoned	PCT	08100-0022/00	돆
NANOTHERAPEUTICS, INC.	Compositions for reparing bone and methods for preparing and using such compositions		Hong Kong	12-Jun-2007		7106279.2	Abandoned	PCT	08100-0022/00	죾
NANOTHERAPEUTICS, INC.	Compositions for reparing bone and methods for preparing and using such compositions		Europe	14-Sep-2006		5724174.7	Abandoned	PCT	08100-0022/00	죾
NANOTHERAPEÚTICS, INC.	Compositions for repaining bone and methods for preparing and using such compositions		Canada	31-Aug-2006		2558200	Abandoned	PCT	08100-0022/00	죾
NANOTHERAPEUTICS, INC.	Process of Forming and Modifying Microparticles and Compositions Produced Thereby		U.S.	19-Apr-2005	8,501,232	10/512,345	issued	PCT	08100-0021/00	8
	Process of Forming and Modifying Microparticles and Compositions Produced Thereby	,	PCT	23-Apr-2003		PCT/US03/11488	Completed	ORO	. 08100-0021/0304	8
	Prevention and treatment of influenza with glutamine antagonist agents		U.S.	30-Sep-2005		11/240,759	Abandoned	ORD	08100-0064/00	DEAD
	Due Diligence investigation into Mowycal Portfolio		U.S.				Transferred	ORD	08100-0041/00	DEAD
	Oral L-Theanine and 5-Hydroxytyptophan Composition		U.S.				Inactive -	ORD	08100-0031/00	DEAD
	Antimicrobial composition		U.S.				inactive	SB	08100-0030/00	DEAD

NUI I PENIU GEIS OUTIPININING INTOIRE POPSEONERINOS DELSITE BIOT ECHTIVOLOSIES, INC.		DEL		DELSITE BIOTECHNOLOGIES, INC.	is comprising anionic polysaccharides DELSITE BIOTECHNOLOGIES, INC.	NANOTHERAPEUTICS, INC.	is comprising anionic polysaccharides DELSITE BIOTECHNOLOGIES, INC.	Is comprising anionic polysaccharides DELSITE BIOTECHNOLOGIES, INC.	is comprising anionic polysaccharides NANOTHERAPEUTICS, INC.	NANOTHERAPEUTICS, INC.	comprising anionic polysaccharides DELSITE BIOTECHNOLOGIES, INC.	comprising anionic polysaccharides NANOTHERAPEUTICS, INC.	comprising anionic polysaccharides NANOTHERAPEUTICS, INC.	comprising anionic polysaccharides NANOTHERAPEUTICS, INC	comprising anionic polysaccharides NANOTHERAPEUTICS, INC	comprising anionic polysaccharides NANOTHERAPEUTICS, INC	ONS COMPRISING ALCC FECTING, AND METHODS FOR THEIR	NANOTHERAPEUTICS, INC	O DAVING FILED MOLECOLAR WEIGHO	NANOTHERAPEUTICS, INC	NANOTHERAPEUTICS, INC	NANOTHERAPEUTICS, INC	R STABILIZER NANOTHERAPEUTICS, INC.	NANOTHERAPEUTICS, INC.					PHARMACEUTICAL COMPOSITIONS COMPRISING PECTINS HAVING HIGH MOLECULAR WEIGHS NANOTHERAPEUTICS, INC. NANOTHERAPEUTICS, INC.				R STABILIZER NANOTHERAPEUTICS, INC								
in-Situ Get Formation of Pectins	In-Situ Gel Formation of Pectins	Delivery of physiological aegents with in-situ gels comprising anionic polysaccharides	In-Situ Gel Formation of Pectins	In-Situ Gel Formation of Pectin	Delivery of physiological aagents with in-situ gels comprising anionic polysacchandes	In-Situ Gel Formation Pectins	Delivery of physiological aagents with in-situ gels comprising anionic polysaccharides	Delivery of physiological aagents with in-situ gels comprising anionic polysaccharides	Delivery of physiological aagents with in-situ gels comprising anionic polysaccharides	in-Situ Gel Formation Pectins	Delivery of physiological agents with in-situ gels comprising anionic polysaccharides	Delivery of physiological agents with in-situ gels comprising anionic polysaccharides	Delivery of physiological agents with in-situ gels comprising anionic polysaccharides	Delivery of physiological agents with in-situ gets comprising anionic polysaccharides	Delivery of physiological agents with in-situ gels comprising anionic polysaccharides	Delivery of physiological agents with in-situ gets comprising anionic polysaccharides	PRODUCTION AND USE	PECTIC GODG ANCE AS A GROWIN FACTOR OF ACIDE OF	AND LOW DEGREES OF METHOXYLATION AND LOW DEGREES OF METHOXYLATION	PECTIC SUBSTANCE AS A GROWTH FACTOR STABILIZER	ALOE PECTINS	ALOE PECTINS	PECTIC SUBSTANCE AS A GROWTH FACTOR STABILIZER	ALOE PECTINS	PECTIC SUBSTANCE AS A GROWTH FACTOR STABILIZER	ALOE PECTINS	PECTIC SUBSTANCE AS A GROWTH FACTOR STABILIZER	PECTIC SUBSTANCE AS A GROWTH FACTOR	PHARMACEUTICAL COMPOSITIONS COMPRIS	ALOE PECTINS	PECTIC SUBSTANCE AS A GROWTH FACTOR STABILIZER	ALOE PECTINS	PECTIC SUBSTANCE AS A GROWTH FACTOR STABILIZER	Reassignment of US Issued Patents	Reassignment of US Patent No. 5,308,838	Reassignment of US Patent No. 5,443,830	Reassignment of US Patent No. 5,409,703	Reassignment of US Patent NO. 5,760,102	Reassignment of US Patent No. 6,313,103	Reassignment of us patent no. 6,777,000	Lypassification of a balancia and a fact from
17-Aug-2004					6/24/2011						19-May-2008		17-May-2006		4/24/2012			14-Aug-2001	04-Apr-2006	06-Nov-2001	27-Jul-1999			30-May-2006	28-Mar-2007			06-Oct-2006		28-Sep-2005	19-Apr-2006	05-Oct-2010									
U.S.	PCT	Korea	Korea	Japan	Japan	Japan	India	Hong Kong	Europe	Europe	Eurasia	China	China	Canada	Canada	Australia	U.S.	U.S.	U.S.	U.S.	U.S.	PCT	PCT	Korea	Korea	Japan	Japan	Hong Kong	Europe	Europe	Europe	Canada	Canada	u.s.	U.S.	U.S.	U.S.	U.S.	U.S.	U.S.	U.S.
24-May-2004 28-Feb-2001	27-Feb-2002	28-Feb-2006	27-Aug-2003	27-Feb-2002	27-Feb-2006	27-Aug-2003	28-Mar-2006	7-Dec-2006	24-May-2004	26-Sep-2003	28-Mar-2006	28-Feb-2006	26-Sep-2003	28-Feb-2006	28-Aug-2003	1-Mar-2006	19-May-2006	4-Jun-1999	3-Jun-1999	24-Jul-1998	13-May-1998	12-May-1999	20-May-1999	12-May-1999	20-May-1999	13-Nov-2000	22-Jan-2001	27-Jul-2001	12-May-1999	30-Nov-2000	20-May-1999	10-Nov-2000	22-Jan-2001								
6777000					4765020						10351		ZL 02807315.0		2439570	,		6274548	7022683	6313103	5929051			10-587423	703040			1034718		1086141	1100820	2331744									
PCT/US04/016146 09/795.897	PCT/US02/05974	10-2006-7004256	10-2003-7011262	2008-243407	2006-524618	2002-567265	1695/DELNP/2006	6113512.6	47530449.9	2780737.9	200600484	2.0048E+11	2807315	2537290	2439570	2004270101		09/325,923	09/325,610	09/122,010	09/078,204	PCT/US99/10335	PCT/US1999/011133	10-2000-7012701	10-2001-7000869	2000-548377	2000-561213	1105264.7	5077100.5	99921889.4	99923246.5	2331744	2338307								
Completed	Completed	Abandoned	Abandoned	Abandoned	issued	Abandoned	Abandoned	Abandoned	Abandoned	Abandoned	Issued	Abandoned	Issued	issued	Issued	Abandoned	Abandoned	Issued	Issued	Abandoned	Issued	Completed	Completed	Abandoned	Abandoned	Abandoned	Abandoned	Abandoned	Abandoned	Issued	Abandoned	Issued	Abandoned	Unfiled	Unfiled	Unfiled	Unfiled	Unfiled	Unfiled	Unfiled	Unfiled
ORD ORD	ORD	PCT	PCT	DIV	PCT	PCT	PCT	PCT	PCT	PCT	PCT	PCT	PCT	PCT	PCT	PCT	DIV	DIV	CON	င္ဆမ	SB	ORD	ORD	PCT	PCT	PCT	PCT	PCT S	DIV	DIV	PCT	PCT	PCT	ORD	ORD	ORD	OR B	SRD	SB	융	88
08100-00/1/01	08100-0071/00	08100-0071/01	08100-0071/00	08100-0071/03	08100-0071/01195	08100-0071/00	08100-0071/01	08100-0071/01	08100-0071/01	08100-0071/00155	08100-0071/01	08100-0071/01	08100-0071/00	08100-0071/01	08100-0071/00131	08100-0071/01	08100-0070/05	08100-0070/03	08100-0070/02	08100-0070/01	08100-0070/00	08100-0070/02	08100-0070/01	08100-0070/02	08100-0070/01	08100-0070/02	08100-0070/01	08100-0070/01	08100-0070/06	08100-0070/02	08100-0070/01	08100-0070/02	08100-0070/01	08100-0062/00	08100-0061/00	08100-0060/00	08100-0059/00	08100-0058/00	08100-0052/00	08100-0051/00	08100-0050/00
GELSITE	GELSITE	GELSITE	GELSITE	GELSITE	GELSITE	GELSITE	GELSITE	GELSITE	GELSITE	GELSITE	GELSITE	GELSITE	GELSITE	GELSITE	GELSITE	GELSITE	GELSITE	GELSITE	GELSITE	GELSITE	GELSITE	GELSITE	GELSITE .	GELSITE	GELSITE	GELSITE	GELSITE	GELSITE	GELSITE	GELSITE	GELSITE	GELSITE	GELSITE	GELSITE	GELSITE	GELSITE	GELSITE	GELSITE	GELSITE	GELSITE	GELSITE

EPIX DELAWARE, INC.	Thienopyridinone Compounds and Methods of Treatment		krae	S-Ont-2005		367681	Ahandanad	0 5	08100-0069/01	PRX-3140
EPIX DELAWARE, INC. EPIX DELAWARE, INC. EPIX DELAWARE, INC. EPIX DELAWARE, INC.	The state of the s			1			The state of the s			
EPIX DELAWARE, INC. EPIX DELAWARE, INC. EPIX DELAWARE, INC. EPIX DELAWARE, INC.	Thienopyridinone Compounds and Methods of Treatment	-	seas	1-Nov-2006		17R996	Abandoned	TOG	08100-0069/00	PRX-3140
EPIX DELAWARE, INC. EPIX DELAWARE, INC. EPIX DELAWARE, INC. EPIX DELAWARE, INC.	Compositions and Methods for Treating CNS Disorders	85	Indonesia	6-Nov-2006		WO200801444	Abandoned	PCT	08100-0069/03	PRX-3140
EPIX DELAWARE, INC. EPIX DELAWARE, INC. EPIX DELAWARE, INC.	Thieropyridinone Compounds and Methods of Treatment	85	Indonesia	5-Apr-2007		WO0200701114	Abandoned	ORD	08100-0069/01	PRX-3140
EPIX DELAWARE, INC. EPIX DELAWARE, INC.	Thienopyridinane Compounds and Methods of Treatment	20.	5	15-Nov-2006		W-00200603219	Abandoned	ORD	08100-0069/00	PRX-3140
EPIX DELAWARE, INC.	Compositions and Methods for Treating CNS Disorders		India	10-Jun-2008		2896/CHENP/2008	Abandoned	PCT	08100-0069/03187	PRX-3140
	Thienopyridinone Compounds and Methods of Treatment		India	7-May-2007		1933/CHENP/2007	Abandoned	PCT	08100-0069/01	PRX-3140
	Thieropyridinone Compounds and Methods of Treatment		India	16-Nov-2006		4228/CHENP/2006	Abandoned	PCT	08100-0069/00187	PRX-3140
EPIX DELAWARE, INC.	Thieropyridinone Compounds and Methods of Treatment	ng .	Hong Kong	18-Feb-2009		9101544	Pending	PCT	08100-0069/03	PRX-3140
EPIX DELAWARE, INC.	Thieropyridinone Compounds and Methods of Treatment	g	Hong Kong	8-Apr-2008		8103886.3	Abandoned	SRI	08100-0069/01	PRX-3140
	Thieropyridinone Compounds and Methods of Treatment	3	Hong Kong	4-Mar-2008		8102395.9	Abandoned	PCT	08100-0069/00	PRX-3140
EPIX PHARMACEUTICALS, INC.	Compositions and Methods for Treating CNS Disorders		Europe	3-Dec-2010		10193700.1	Abandoned	DIV	08100-0069/04	PRX-3140
	Compositions and Methods for Treating CNS Disorders		Europe	6-Nov-2006		6827533.8	Abandoned	PCT	08100-0069/03155	PRX-3140
EPIX DELAWARE, INC.	Thienopyridinone Compounds and Methods of Treatment		Europe	3-May-2007		5801809.4	Abandoned	PCT	08100-0069/01	PRX-3140
	Thienopyridinone Compounds and Methods of Treatment			15-Nov-2006		5779361.4	Pending	PCT	08100-0069/00155	PRX-3140
The state of the s	Compositions and Methods for Treating CNS Disorders		Eurasia	9-Jun-2008		200801302	Abandoned	PCT	08100-0069/03	PRX-3140
EPIX DELAWARE, INC.	Thieropyridinone Compounds and Methods of Treatment		H	11-May-2008		PCT/768/2008	Abandoned	PCT	08100-0069/03	PRX-3140
EPIX DELAWARE, INC.	Thienopyridinone Compounds and Methods of Treatment		Egypt	8-Apr-2007		349/2007	Abandoned	ORD	08100-0069/01	PRX-3140
EPIX DELAWARE, INC.	Thieropyridinone Compounds and Methods of Treatment		-	15-Nov-2006		1090/2006	Abandoned	PCT	08100-0069/00	PRX-3140
	Compositions and Methods for Treating CNS Disorders	8	-	10-Jun-2008		10.026	Abandoned	PCT	08100-0069/03139	PRX-3140
EPIX DELAWARE, INC.	Compositions and Methods for Treating CNS Disorders	8	Colombia	10-Jun-2008		08 058.972	Abandoned	РСТ	08100-0069/03	PRX-3140
EPIX DELAWARE, INC.	Thieropyridinone Compounds and Methods of Treatment	8		4-May-2007		07.044,404	Abandoned	ORD	08100-0069/01	PRX-3140
EPIX DELAWARE, INC.	Thienopyridinone Compounds and Methods of Treatment	0,	Colombia	14-Dec-2006		6125518	Abandoned	PCT	08100-0069/00	PRX-3140
*	Compositions and Methods for Treating CNS Disorders			12-Jun-2008		2.0068E+11	Abandoned	PCT	08100-0069/03	PRX-3140
EPIX DELAWARE, INC.	Thienopyridinone Compounds and Methods of Treatment			15-May-2007		2.0058E+11	Abandoned	PCT	08100-0069/01	PRX-3140
	Thienopyridinone Compounds and Methods of Treatment			24-Nov-2006		2.0058E+11	Abandoned	PCT	08100-0069/00	PRX-3140
EPIX DELAWARE, INC.	Compositions and Methods for Treating CNS Disorders		Chile	4-Apr-2007		-350449	Opposed	ORD	08100-0069/03	PRX-3140
EPIX DELAWARE, INC.	Thienopyridinone Compounds and Methods of Treatment		Chile	6-Oct-2005		2616-2005	Abandoned	ORD	08100-0069/01	PRX-3140
EPIX DELAWARE, INC.	Thienopyridinone Compounds and Methods of Treatment		Chile	9-Nov-2006		427852	Abandoned	PCT	08100-0069/00	PRX-3140
EPIX DELAWARE, INC.	Compositions and Methods for Treating CNS Disorders	8/12/2014	Canada	9-May-2008	2,629,312	2629312	Issued	PCT	08100-0069/03131	PRX-3140
EPIX DELAWARE, INC.	Thienopyridinone Compounds and Methods of Treatment	ū		5-Apr-2007		2583353	Abandoned	PCT	08100-0069/01131	PRX-3140
EPIX DELAWARE, INC.	Thieropyridinone Compounds and Methods of Treatment		-	16-Nov-2006	2,567,268	2567268	Issued	PCI	08100-0069/00110	PRX-3140
EPIX DELAWARE, INC.	Compositions and Methods for Treating CNS Disorders		Brazil	6-Nov-2006		PI0618493-6	Pending	PCT	08100-0069/03123	PRX-3140
EPIX DELAWARE, INC.	Thieropyridinone Compounds and Methods of Treatment		_	9-Apr-2007		PI0516130-4	Abandoned	PCT	08100-0069/01	PRX-3140
EPIX DELAWARE, INC.	Thieropyridinone Compounds and Methods of Treatment			16-Nov-2006		Pl0510022-4	Pending	PCT	08100-0069/00123	PRX-3140
EPIX DELAWARE, INC.	Compositions and Methods for Treating CNS Disorders	a	Australia	8-May-2008		2006315854	Abandoned	PG G	08100-0069/03110	PRX-3140
EPIX DELAWARE, INC.	Thieropyridinone Compounds and Methods of Treatment		Australia	12-Apr-2007		2005294329	Abandoned	PCT	08100-0069/01	PRX-3140
	Thienopyridinone Compounds and Methods of Treatment	a 6/14/2012	Australia	30-Oct-2006		2005252632	Issued	PCT	08100-0069/00	PRX-3140
	Compositions and Methods for Treating CNS Disorders	8	Argentina	9-Nov-2006		60104925	Abandoned	ORD	08100-0069/03	PRX-3140
EPIX DELAWARE, INC.	Thienopyridinone Compounds and Methods of Treatment	8		6-Oct-2005		P050104240	Abandoned	PCT	08100-0069/01	PRX-3140
EPIX DELAWARE, INC.	Compositions and Methods for Treating CNS Disorders			14-May-2008		80300	Abandoned	PCT	08100-0069/03	PRX-3140
EPIX DELAWARE, INC.	Thienopyridinone Compounds and Methods of Treatment			24-Apr-2007		70246	Abandoned	PCT	08100-0069/01	PRX-3140
EPIX DELAWARE, INC.	Thienopyridinone Compounds and Methods of Treatment			13-Dec-2006		60622	Abandoned .	PCT	08100-0069/00	PRX-3140
	Purification of Influenza Viral Antigens		,	11-Dec-2007		PCT/US07/025487	Completed	PCT	08100-0072/00	PRX-3140
DELSITE BIOTECHNOLOGIES, INC.	Delivery of physiological aagents with in-situ gets comprising anionic polysaccharides			29-Aug-2003		10/652,873	Abandoned	유	08100-0071/02	GELSITE
NANOTHERAPEUTICS, INC.	Delivery of physiological aagents with in-situ gels comprising anionic polysaccharides	24-Feb-2009	U.S.	29-Aug-2003	7494669	10/652,622	Issued	CIP	08100-0071/01	GELSITE

Algam Composition and Methods for Treatment EXYCREANISES EXYCREANISES 5 Riceas Theoropylidronic Allegrounds of Methods for Treatment EXYCREANISES EXYCREANISES 6 Riceas Theoropylidronic Allegrounds and Methods for Treatment EXYCREANISES EXYCREANISES Makerias Compositions and Methods for Treatment EXYCREANISES EXYCREANISES Makerias Comp		Philippines Philippines Russia Russia Russia Russia Russia Russia Singapore Singapore Singapore South Africa South Africa South Africa South Africa Taiwan Taiwan Taiwan Taiwan Trailand Tinidad and Tinidad and Trobago Tinidad and Tinidad and Trobago Tinidad and	5-Oct-2005 5-Apr-2005 5-Apr-2006 6-Nov-2006 6-Nov-2006 4-May-2007 6-May-2007 6-May-2007 6-May-2007 6-May-2006 9-Nov-2006 9-Nov-2006 8-Nov-2006 9-Oct-2007 23-Apr-2008	127332 2006/09213 2008/09213 2007/03596 2008/04851	2007116950 92287 200702579-4 200702579-4 200609213 200609213 200700596 200804951 94136238 95141449 104989 601005551 TTIAZ006000227 TTIAZ006000248 TTIAZ00700248	Abandoned	PCT PCT	08100-0069/01 08100-0069/03 08100-0069/01	PRX-3140 PRX-3140
Jagan Chrosophifonic Composite and Mandos of Trainment EDYN DELAWARE, INC. 5 Koms Theorophylinous and Mandos for Trainment EDYN DELAWARE, INC. 5 Koms Theorophylinous Composite and Mandos of Trainment EDYN DELAWARE, INC. 6 Koms Theorophylinous Composite and Mandos of Trainment EDYN DELAWARE, INC. Makelos Composition and Mandos for Trainfay OTIS Disorders EDYN DELAWARE, INC. Makelos Composition and Mandos for Trainfay OTIS Disorders EDYN DELAWARE, INC. Makelos Composition and Mandos for Trainfay OTIS Disorders EDYN DELAWARE, INC. Makelos Composition and Mandos for Trainfay OTIS Disorders EDYN DELAWARE, INC. Makelos Composition and Mandos for Trainfay OTIS Disorders EDYN DELAWARE, INC. Mayor Composition and Mandos for Trainfay OTIS Disorders EDYN DELAWARE, INC. Mayor Theoryprishons of Composite and Mandos of Trainfay EDYN DELAWARE, INC. Mayor Theoryprishons of Composition and Mandos of Trainfay EDYN DELAWARE, INC. Mayor Theoryprishons of Composition and Mandos of Trainfay EDYN DELAWARE, INC. Mayor Theoryprishons of Composition and Mandos of Trainfay EDYN DELAWARE, I		Philippines Philippines Russia Singapore Singapore South Africa South Africa South Africa South Africa Russiand Taiwan Ta	5-Oct-2005 5-Apr-2007 5-Apr-2007 6-Nov-2006 6-Nev-2006 4-May-2007 6-Jun-2008 9-Nov-2006 8-Nov-2006 8-Nov-2006 8-Nov-2006 8-Oct-2007 23-Apr-2008	127332 2006/09213 2008/09213 2007/03596 2008/04951	2007116950 92287 2007025794 -266778 200609213 200702596 200804951 94136238 95141449 104989 601005551 TTIAZ00600027 TTIAZ00600028	Abandoned	PCT PCT	08100-0069/01 08100-0069/03	PRX-3140 PRX-3140
Jagan Composition to Composition of Manhand (Composition of Manhand Composition of Manhand Composition of Manhand (Composition of Manhand Composition of Manhand Composition of Manhand (Composition of Manhand Composition of Manhand Composition of Manhand (Composition of Manhand Composition of Manhand Composition of Manhand Composition of Manhand Composition of Manhand (Composition of Manhand Composition of Manh		Philippines Philippines Russia Singapore Singapore Singapore Singapore Singapore Talwan Talwan Talwan Talwan Talwan Talwan Talwan Trinidad and Trinidad and Trinidad on Trinidad on Trinidad on	5-Oct-2005 5-Apr-2005 5-Apr-2006 6-Nov-2006 6-Nov-2006 6-Nov-2006 6-Nov-2006 6-Nov-2006 6-Oct-2005 9-Nov-2006 8-Nov-2006 8-Nov-2006 8-Nov-2006	127332 2006/09213 2008/09213 2007/03596 2008/04851	2007116950 92287 2007025794 200609213 200703596 200804551 94138238 95141449 104889 601005551 TTIAZ00600227 TTIAZ00600227	Abandoned	PCT PCT	08100-0069/01	PRX-3140
Jagan Composition and Markode of Treatment EPIX.DELAWARE, N.C. Noise Composition and Markode of Treatment EPIX.DELAWARE, N.C. Noise Composition and Markode of Treatment EPIX.DELAWARE, N.C. National Composition and Markode of Treatment EPIX.DELAWARE, N.C. Throughyridionae Composition and Markode of Treatment EPIX.DELAWARE, N.C. EPIX.DELAWARE, N.C. Throughyridionae Composition and Markode of Treatment EPIX.DELAWARE, N.C.		Philippines Philippines Russia Russia Russia Singapore Singapore Singapore South Africa South Africa South Africa South Africa Talwan Talwan Trailand Trailand Trailand Trailand	6-Oct-2006 5-Apr-2007 6-Nev-2006 6-Nev-2006 6-Nev-2006 6-Mey-2007 6-Jun-2008 9-Nov-2006 8-Nov-2006 13-Nov-2006	127332 2006405213 2007/03596 2008/04851	2007116850 92287 200702579-4 -266778 200600213 2007002513 2007103596 200800451 200800451 20104594 95141449 104889 861005551 104889	Abandoned Abandoned Abandoned Abandoned Abandoned Abandoned Abandoned Abandoned	PCT		-
Jagan Compositions Composition of Treatment Kosas Theorypidens and Markots of Treating CIES Disorders Kosas Compositions and Markots of Treating CIES Disorders Kosas Compositions and Markots of Treating CIES Disorders Markots Compositions and Markots of Treating CIES Disorders Markots Compositions and Markots of Treating CIES Disorders Markots Cies Catagogation and Markots of Treating CIES Disorders Markots Cies Catagogation and Markots of Treating CIES Disorders Markots Cies Catagogation and Markots of Treating CIES Disorders Markots Cies Catagogation and Markots of Treating CIES Disorders Markots Cies Catagogation and Markots of Treating CIES Disorders Markots Cies Catagogation and Markots of Treating CIES Disorders Markots Cies Catagogation and Markots of Treating CIES Disorders Markots Cies Catagogation and Markots of Treating CIES Disorders Markots Cies Catagogation and Markots of Treating CIES Disorders Markots Cies Catagogation and Markots of Treating CIES Disorders Markots Cies Catagogation and Markots of Treating CIES Disorders Markots Cies Catagogation and Markots of Treating CIES Disorders Markots Cies Catagogation and Markots of Treating CIES Disorders Markots Cies Catagogation and Markots of Treating CIES Disorders Markots Cies Catagogation and Markots of Treating CIES Disorders Markots Cies Catagogation and Markots of Treating CIES Disorders Markots Cies Catagogation and Markots of Treating CIES Disorders Markots Cies Catagogation and Markots of Treating CIES Disorders Markots Cies Catagogation and Markots of Treating CIES Disorders Markots Cies Catagogation and Markots of Treating CIES Disorders Markots Cies Catagogation and Markots of Treating CIES Disorders Markots Cies Catagogation and Markots of Treating CIES Disorders Markots Cies Catagogation and Markots of Treating CIES Disorders Markots Cies Catagogation and Markots of Treating CIES Disorders Markots Cies Catagogation and Markots of Treating CIES Disorders Markots Cies Catagogation and Markots of Treating CIES Disorders Markots Cies Catag		Philippines Philippines Russia Russia Russia Singapore Singapore Singapore Singapore Singapore South Africa South Africa South Africa Taiwan Taiwan Thailarid Thailarid	6-Oct-2005 5-Apr-2007 6-Nev-2006 6-Nev-2006 6-Nev-2006 6-Un-2008 6-Oct-2006 9-Nev-2006 8-Nev-2006	127332 2006/05/213 2007/03596 2008/04851	2007116950 92287 200702579-4 -266778 2006002613 2006002613 2007103596 2008004951 95141449 95141449 104886 601005551	Abandoned Abandoned Abandoned Abandoned Abandoned Abandoned		08100-0069/00	PRX-3140
Jagan Composition Composada and Mahoda of Treatment Kosas Composition of Treatment Kosas Composition and Mahoda of Treatment Makodo BESCO10 Composition and Mahoda of Treatment Makodo Composition and Mahoda of Treatment PET Treatment Composition and Mahoda of Treatment PET Treatment Composition and Mahoda of Treatment PROSE MAMAE INC. PRinciplem Treatment Composition and Mahoda of Treatment PROSE MAMAE INC. PRinciplem Composition and Mahoda of Treatment PROSE MAMAE INC. PRINCIPLAMAE IN		Philippines Philippines Russia Russia Russia Russia Russia Singapore Singapore Singapore South Africa South Africa South Africa South Africa Talwan Talwan Trailerid	5-Nev-2005 5-Nev-2005 5-Nev-2006 6-Nev-2006 6-Nev-2006 6-Um-2008 9-Nev-2006	127332 2006/05/13 2007/03596 2008/04551	2007/16850 92287 2007/02579-4 -265778 2006/09213 2007/02596 2008/04951 94138238 95141449 104989	Abandoned Abandoned Abandoned Abandoned Abandoned	ORD	08100-0069/03	PRX-3140
Jagon Compositions Composition and Methods of Treatment EPIX DELAWARE, INC. Composition and Methods of Treat		Philippines Philippines Russia Russia Russia Russia Singapore Singapore Singapore Singapore South Africa South Africa South Africa South Africa Talwan Talwan	6-Oct-2005 16-May-2005 5-Apr-2007 6-Nov-2006 6-Nov-2006 4-May-2007 6-Jun-2008 6-Oct-2005	127332 127332 2006/09213 2007/03596 2007/03596	2007/16850 92287 2007/02579-4 -266778 2006/09213 2007/03596 2008/04551 94/182298 95/14/1449	Abandoned Abandoned Abandoned Abandoned	ORD	08100-0069/01	PRX-3140
Jugan Compositione Composition and Methods of Treatment Kossa Kossa Kossa Composition and Methods of Treatment Kossa Composition and Methods of Treatment Kossa Composition and Methods of Treatment Methods M		Philippines Philippines Philippines Russia Russia Russia Russia Russia Russia Russia Russia Singapore	6-Oct-2005 16-May-2005 5-Apr-2007 6-Nov-2006 6-Nov-2006 4-May-2007 6-Jun-2008	127332 2006095213 200703596 200204951	2007118950 92287 200702579-4 -266778 200609213 200702596 200804951 84138238	Abandoned Abandoned Abandoned	ORD	08100-0069/03	PRX-3140
Jugan Chropositions of Disposes Kosas Kosa		Philippines Philip	6-Oct-2005 16-May-2005 5-Apr-2007 6-Nov-2006 6-Nov-2006 4-May-2007 6-Jun-2008	127332 2006/09213 2007/03596 2008/04951	2007/16850 92287 2007/25/9-4 -266778 2006/09213 2007/20596 2008/4551	Abandoned Abandoned	PCT	08100-0069/01	PRX-3140
Jagan Composition and Marbods of Treatment Koses Composition and Marbods of Treatment Makedon Composition and Marbods of Treatment Marbods Composition and Marbods of T		Philippines Philippines Russia Russia Russia Singapore Singapore Singapore South Africa South Africa	5-Apr-2005 5-Apr-2007 5-Nov-2006 6-Nov-2006 6-Nov-2006	127332 127332 200609213 200703596	2007118850 92287 200702579-4 -266778 200609213 2007103596	Abandoned	PCT	08100-0069/03	PRX-3140
Jagan Composition and Marthods of Treatment EPIX DELAWARE, INC. This opposition and Marthods of Treatment EPIX DELAWARE, INC. This opposition and Marthods of Treatment EPIX DELAWARE, INC. This opposition and Marthods of Treatment EPIX DELAWARE, INC. This opposition and Marthods of Treatment EPIX DELAWARE, INC. This opposition and Marthods for Treatment EPIX DELAWARE, INC. This opposition and Marthods for Treatment EPIX DELAWARE, INC. This opposition and Marthods for Treatment EPIX DELAWARE, INC. This opposition and Marthods for Treatment EPIX DELAWARE, INC. This opposition and Marthods for Treatment EPIX DELAWARE, INC. This opposition and Marthods for Treatment EPIX DELAWARE, INC. This opposition and Marthods for Treatment EPIX DELAWARE, INC. This opposition and Marthods of Treatment EPIX DELAWARE, INC. This opposition and Marthods of Treatment EPIX DELAWARE, INC. This opposition and Marthods of Treatment EPIX DELAWARE, INC. This opposition and Marthods of Treatment EPIX DELAWARE, INC. This opposition and Marthods of Treatment EPIX DELAWARE, INC. This opposition and Marthods of Treatment EPIX DELAWARE, INC. This opposition and Marthods of Treatment EPIX DELAWARE, INC. This opposition and Marthods of Treatment EPIX DELAWARE, INC. This opposition and Marthods of Treatment EPIX DELAWARE, INC. This opposition and Marthods of Treatment EPIX DELAWARE, INC. This opposition and Marthods of Treatment EPIX DELAWARE, INC. This opposition and Marthods of Treatment EPIX DELAWARE, INC. This opposition and Marthods of Treatment EPIX DELAWARE, INC. This opposition and Marthods of Treatment EPIX DELAWARE, INC. This opposition and Marthods of Treatment EPIX DELAWARE, INC. This opposition and Marthods of Treatment EPIX DELAWARE, INC. This opposition and Marthods of Treatment EPIX DELAWARE, INC. This opposition and Marthods of Treatment EPIX DELAWARE, INC. This opposition and Demonds and Marthods of Treatment EPIX DELAWARE, INC. EPIX DELAWARE, INC. EPIX DELAWARE, INC. EPIX DELAWARE, INC. EPIX DELA		Philippines Philippines Russia Russia Russia Singapore Singapore Singapore South Africa	5-Apr-2005 5-Apr-2007 6-Nov-2006 6-Nov-2006	127332	2007118950 92287 200702579-4 -266778 2006/09213		PCT	08100-0069/01	PRX-3140
Japan Chronopylidinos Compozeta and Mehoda of Treatment EPK DELAWARE, INC.		Philippines Philippines Philippines Russia Russia Russia Singapore Singapore Singapore	6-Oct-2005 16-May-2005 5-Apr-2007 6-Nov-2006	127332	2007118850 92287 200702579-4 -286778	Lapsed	PCT	08100-0069/00	PRX-3140
Japan Compositions of Compositions of Healing CNS Disorders Koses Phinospiridinos Compositions of Methods of Treating CNS Disorders Koses Compositions and Methods for Treating CNS Disorders Makelon Compositions and Methods for Treating CNS Disorders Makelon Republication Republications Compositions and Methods for Treating CNS Disorders Makelon Republication Republications Compositions and Methods for Treating CNS Disorders Makelon Republication Republications Compositions and Methods for Treating CNS Disorders Makelon Republication Republications Compositions and Methods for Treating CNS Disorders Makelon Republication Republications Compositions and Methods for Treating CNS Disorders Makelon Republication Republications Compositions and Methods for Treating CNS Disorders Makelon Republication Republications Republication Republicati		Philippines Philippines Russia Russia Russia Singapore Singapore	16-May-2005 5-Apr-2007	127332	2007116950 92287 200702579-4	Abandoned	PCT	08100-0069/03	PRX-3140
Jagon Compositions of Althrode of Treatment EPIX.DELAWARE, INC.		Philippines Philippines Philippines Russia Russia Russia Singapore	6-Oct-2005 16-May-2005	127332	2007116950 92287	Abandoned	PCT	08100-0069/01	PRX-3140
Japan Compositions of Methods of Treatment EPIX.DELAWARE, INC.	Thienopyridinone Thienopyridinone Thienopyridinone	Philippines Philippines Russia Russia	6-Oct-2005		2007116950	Lapsed	PCT	08100-0069/00	PRX-3140
Japan Compositions and Methods of Treatment EPIX DELAWARE, INC.	Thieropyridinone Thieropyridinone	Philippines Philippines Russia				Abandoned	PCT	08100-0069/01	PRX-3140
Jagan Interopriétione Compourés and Methods of Treatment EPIX DELAWARE, INC. Compositions and Methods for Treatment EPIX DELAWARE, INC. Compositions and Methods of Treatment EPIX DEL	Thienopyridinone	Philippines Philippines	15-Dec-2006		2006144867	Abandoned	PCT	08100-0069/00	PRX-3140
Japan Diesopriditione Compounds and Methods of Treatment EPIX DELAWARE, INC. Japan Compositions and Alethods for Treating CNS Disorders Korea Thieropyriditione Compounds and Methods of Treatment EPIX DELAWARE, INC. Korea Compositions and Methods for Treating CNS Disorders Makerica Compositions and Methods for Treating CNS Disorders Mexico Baszonio Compositions and Methods of Treatment EPIX DELAWARE, INC. Mexico Baszonio Compositions and Methods of Treatment EPIX DELAWARE, INC. Mexico Delaware, Indicate EPIX DELAWARE, INC. EPIX DELAW		Philippines	2-May-2008	-	1-2008-501046	Abandoned	PCT	08100-0069/03	PRX-3140
Japan Thiotopyridinore Compounts and Methods of Treathern Korea Thiotopyridinore Compounts and Methods of Treathern Thioto	Thienopyridinone		10-Apr-2007		1-2007-500770	Abandoned	PCT	08100-0069/01	PRX-3140
Japan Compositions and Methods of Treating CNR Disorders Korea Theropyridinone Compounds and Methods of Treating CNR Disorders Korea Theropyridinone Compounds and Methods of Treating CNR Disorders Korea Compositions and Methods for Treating CNR Disorders Mastroco Compositions and Methods for Treating CNR Disorders Mexico Compositions and Methods for Treating CNR Disorders Mexico Disorders Compounds and Methods of Treating CNR Disorders Mexico Disorders Compounds and Methods for Treating CNR Disorders Mexico Disorders Compounds and Methods of Treating CNR Disorders Mexico Disorders Compounds and Methods of Treating CNR Disorders Mexico Disorders Compounds and Methods of Treating CNR Disorders Mexico Disorders Compounds and Methods of Treating CNR Disorders Mexico Disorders Compounds and Methods of Treating CNR Disorders Mexico Disorders Compounds and Methods of Treating CNR Disorders Mexico Disorders Compounds and Methods of Treating CNR Disorders Mexico Disorders Compounds and Methods of Treating CNR Disorders Mexico Disorders Compounds and Methods of Treating CNR Disorders Mexico Disorders Compounds and Methods of Treating CNR Disorders Mexico Disorders Compounds and Methods of Treating CNR Disorders Mexico Disorders Compounds and Methods of Treating CNR Disorders Nowaey Theropyridinone Compounds and Methods of Treating CNR Disorders Monaey Compositions and Methods of Treating CNR Disorders Mexico Disorders Compounds and Methods of Treating CNR Disorders Monaey Compositions and Methods of Treating CNR Disorders Monaey Compo	Thienopyridinone	Philippines	15-Nov-2006		1-2006-502274	Abandoned	PCT	08100-0069/00	PRX-3140
Japan Theropyridinore Compounds and Methods of Treating CNS Disorders Korea Thioropyridinore Compounds and Methods for Treating CNS Disorders Korea Compositions and Methods for Treating CNS Disorders Korea Compositions and Methods for Treating CNS Disorders Methods Compositions and Methods of Treating CNS Disorders Methods Compositions and Methods COMPOSITION COMP	Thienopyridinone	PCT	6-Oct-2005		PCT/US2005/035935	Completed	ORD	08100-0069/01	PRX-3140
Japan Theropyridinore Compounds and Methods of Treating CNS Disorders Korea Thioropyridinore Compounds and Methods of Treating CNS Disorders Korea Compositions and Methods for Treating CNS Disorders Korea Compositions and Methods for Treating CNS Disorders Makeico Compositions and Methods for Treating CNS Disorders Mexico Compositions and Methods for Treating CNS Disorders Mexico Compositions and Methods for Treating CNS Disorders Mexico Compositions and Methods of Treating CNS Disorders Mexico Compositions and Methods for Treating CNS Disorders Mexico Compositions and Methods of Treating CNS Disorders Mexico Com	Thienopyridinone	PCT	16-May-2005		PCT/US05/17121	Completed	PCT	08100-0069/00	PRX-3140
Japan Theopyridinoe Compounds and Methods of Treating CNS Disorders Korea Thionopyridinoe Compounds and Methods of Treating CNS Disorders Korea Compositions and Methods for Treating CNS Disorders Korea Compositions and Methods of Treating CNS Disorders Makedoo Compositions and Methods of Treating CNS Disorders Mexico Compositions and Methods of Treating CNS Disorders Thieropyridinone Compounds and Methods of Treatinent New Zealand Compositions and Methods of Treating CNS Disorders Mexico Compositions and Methods of Treatinent Thieropyridinone Compounds and Methods of Treatinent Thieropyridinone Compounds and Methods of Treatinent Thieropyridinone Compounds and Methods of Treatinent Migrita Compositions and Methods of Treatinent Thieropyridinone Compounds and Methods of Treatinent Thieropyridinone Compounds and Methods of Treatinent Thieropyridinone Compounds and Methods of Treatinent EPIX DELAWARE, INC.	Compositions and	Norway	10-Jun-2008		20082679	Abandoned	PCT	08100-0069/03	PRX-3140
Japan Compositions and Methods of Treating CNR Disorders Korea Compositions and Methods of Treating CNR Disorders Korea Compositions and Methods of Treating CNR Disorders Korea Compositions and Methods for Treating CNR Disorders Methods Compositions and Methods for Treating CNR Disorders Methods Compositions and Methods for Treating CNR Disorders Methods Security Compositions and Methods for Treating CNR Disorders Methods Security Compositions and Methods for Treating CNR Disorders Methods Security Compositions and Methods for Treating CNR Disorders Methods Security Compositions and Methods for Treating CNR Disorders Methods Security Compositions and Methods of Treating CNR Disorders Methods Security Compositions and Methods of Treating CNR Disorders Methods Security Compositions and Methods of Treating CNR Disorders Methods Of 1-Feb-2008 Methods Of 1-Feb-2008 Methods Of 1-Feb-2008 Methods Of 1-Feb-2008 Thieropyridinone Compounds and Methods of Treatinent Methods Of 1-Feb-2008 Thieropyridinone Compounds and Methods of Treatinent Methods Of 1-Feb-2008 Thieropyridinone Compounds and Methods of Treatinent Methods Of Treatinent Methods Of Treatinent Methods Of Treatinent Compositions and Methods of Treatinent Methods Of Treatinent Methods Of Treatinent Compositions and Methods of Treatinent Methods Of Treatinent Methods Of Treatinent Disorders Thieropyridinone Compounds and Methods of Treatinent EPIX DELAWARE, INC. EPIX DELAWARE, INC. EPIX DELAWARE, INC. EPIX DELAWARE, INC. Methods Of Treatinent EPIX DELAWARE, INC. EPIX DELAWARE, INC. EPIX DELAWARE, INC. EPIX DELAWARE, INC. Methods Of Treatinent EPIX DELAWARE, INC. EPIX DELAWARE, INC. EPIX DELAWARE, INC. EPIX DELAWARE, INC. Thieropyridinone Compounds and Methods of Treatinent EPIX DELAWARE, INC. EPIX DELAWARE,	Thienopyridinone	Norway	6-Oct-2005		20072348	Abandoned	PCT	08100-0069/01	PRX-3140
Japan Compositions and Methods of Treatment EPIX DELAWARE, INC. Japan Compositions and Methods for Treatment Compounds and Methods of Treatment Korea Thieropyridinone Compounds and Methods of Treatment Korea Compositions and Methods for Treatment Compounds and Methods of Treatment Korea Compositions and Methods for Treatment Compounds and Methods of Treatment Methods Compositions and Methods for Treatment Compounds and Methods of Treatment Methods S52010 Compositions and Methods for Treatment Compounds and Methods of Treatment Methods S52010 Compositions and Methods of Treatment Compounds and Methods of Treatment Methods Compositions and Methods for Treatment Compounds and Methods of Treatment Compo	Thienopyridinone	Norway	15-Dec-2006		20065814	Abandoned	PCT	08100-0069/00	PRX-3140
Japan Compositions and Methods of Treating CNS Disorders Korea Theropyridinone Compounds and Methods of Treating CNS Disorders Korea Compositions and Methods for Treating CNS Disorders Korea Compositions and Methods for Treating CNS Disorders Korea Compositions and Methods for Treating CNS Disorders Mexico Compositions and Methods of Treating CNS Disorders Mexico Compositions and	Compositions and	Nigeria	6-Nov-2006		NG/C/2008/236	Abandoned	PCT	08100-0069/03	PRX-3140
Japan Compositions and Methods of Treatment EPIX DELAWARE, INC. Korea Theropyridinone Compounds and Methods of Treatment Korea Compositions and Methods for Treatment Korea Compositions and Methods and Methods of Treatment Korea Compositions and Methods of Treatment Korea Compositions and Methods for Treatment Methods Compositions and Methods for Treatment Thisropyridinone Compounds and Methods of Treatment Methods Delaware, INC. Methods Delaware, INC. Methods O11-Feb-2008 Thisropyridinone Compounds and Methods of Treatment Methods Compositions and Methods of Treatment Methods Compositions and Methods of Treatment Methods O11-Feb-2008 Thisropyridinone Compounds and Methods of Treatment EPIX DELAWARE, INC.	Thienopyridinone	Nigeria	6-Apr-2007		-591875	Abandoned	PCT	08100-0069/01	PRX-3140
Japan Theropyridinore Compounds and Methods of Treatment EPIX DELAWARE, INC. 5 Korea Theropyridinore Compounds and Methods for Treatment Compounds and Methods for Treatment Compounds and Methods of Treatment EPIX DELAWARE, INC. Korea Compositions and Methods for Treatment EPIX DELAWARE, INC. Korea Compositions and Methods for Treatment EPIX DELAWARE, INC. Makeico Compositions and Methods for Treatment EPIX DELAWARE, INC. Mexico Delawy 2007 Theropyridinore Compounds and Methods of Treatment EPIX DELAWARE, INC. Microcco U2-May-2007 Theropyridinore Compounds and Methods of Treatment EPIX DELAWARE, INC. Microcco O1-Feb-2008 Theropyridinore Compounds and Methods of Treatment EPIX DELAWARE, INC. Mew Zealand Theropyridinore Compounds and Methods of Treatment EPIX DELAWARE, INC. New Zealand Compositions and Methods for Treatment EPIX DELAWARE, INC.		Nigeria	16-Nov-2006	NG/C/2007/688	-598114	Lapsed	PCT	08100-0069/00	PRX-3140
Japan Theropyridinore Compounds and Methods of Treatment EPIX DELAWARE, INC. Japan Compositions and Methods of Treatment (SNS Disorders Korea Thieropyridinore Compounds and Methods of Treatment Korea Compositions and Methods of Treatment Korea Compositions and Methods of Treatment Korea Compositions and Methods for Treatment (SNS Disorders Mexico Compositions and Methods for Treatment (SNS Disorders Mexico BES/2010 Compositions and Methods of Treatment Mexico ES/2010 Compositions and Methods of Treatment (SNS Disorders Compositions and Methods for Treatment (SNS Disorders Mexico BES/2010 Compositions and Methods of Treatment (SNS Disorders Thieropyridinone Compounds and Methods of Treatment (SNS Disorders) Thieropyridinone Compounds and Methods of Treatment (SNS Disorders) DELAWARE, INC. EPIX DELAWARE, INC. EPIX DELAWARE, INC. EPIX DELAWARE, INC.	Compositions and	New Zealand	5-Jun-2008		568869	Abandoned	PCT	08100-0069/03	PRX-3140
Japan Theropyridinore Compounds and Methods of Treatment EPIX DELAWARE, INC. Japan Compositions and Methods of Treatment Compounds and Methods of Treatment Korea Thieropyridinore Compounds and Methods of Treatment Korea Compositions and Methods of Treatment Korea Compositions and Methods of Treatment Korea Compositions and Methods for Treatment Compounds and Methods of Treatment Mexico Mexico EpiX Delaware, INC. Mexico EpiX Delaware, INC. Mexico EpiX Delaware, INC. Mexico Compositions and Methods for Treatment EpiX Delaware, INC. Mexico EpiX Delaware, INC. Mexico EpiX Delaware, INC. Mexico Compositions and Methods of Treatment EpiX Delaware, INC. Mexico Compositions and Methods of Treatment EpiX Delaware, INC. Mexico Compositions and Methods of Treatment EpiX Delaware, INC. Mexico Compositions and Methods of Treatment EpiX Delaware, INC. Mexico Compositions and Methods of Treatment EpiX Delaware, INC. Mexico Compositions and Methods of Treatment EpiX Delaware, INC. Mexico Compositions Compounds and Methods of Treatment EpiX Delaware, INC. Mexico Compositions Compounds and Methods of Treatment EpiX Delaware, INC. Thieropyridinone Compounds and Methods of Treatment EpiX Delaware, INC.	Thienopyridinone	New Zealand	6-Oct-2005		554927	Abandoned	PCT	08100-0069/01	PRX-3140
Japan Compositions and Methods of Treating CNR Disorders Korea Compositions and Methods of Treating CNR Disorders Korea Thieropyridinone Compounds and Methods of Treating CNR Disorders Korea Compositions and Methods of Treating CNR Disorders Makedo Compositions and Methods for Treating CNR Disorders Mexico Trieropyridinone Compounds and Methods of Treating CNR Disorders Mexico Security Compositions and Methods for Treating CNR Disorders Mexico Security Compositions and Methods for Treating CNR Disorders Mexico Security Compositions and Methods of Treating CNR Disorders Mexico Security Compositions and Methods of Treating CNR Disorders Mexico Security Compositions and Methods of Treating CNR Disorders Mexico Security Compositions and Methods of Treating CNR Disorders Mexico Security Compositions and Methods of Treating CNR Disorders Mexico Security Compositions and Methods of Treating CNR Disorders Mexico Security Compositions and Methods of Treating CNR Disorders Mexico Security Compositions and Methods of Treating CNR Disorders Mexico Security Compositions and Methods of Treating CNR Disorders Mexico Security Compositions and Methods of Treating CNR Disorders Mexico Security Compositions and Methods of Treating CNR Disorders Mexico Security Compositions and Methods of Treating CNR Disorders Mexico Security Compositions and Methods of Treating CNR Disorders Mexico Security CNR Disor		New Zealand	27-Oct-2006		550845	Abandoned	PCT	00/6900-00180	PRX-3140
Japan Theropyridinore Compounds and Methods of Treatment EPIX DELAWARE, INC. Japan Compositions and Methods for Treating CNS Disorders Korea Theropyridinore Compounds and Methods of Treatment Korea Compositions and Methods of Treatment Korea Compositions and Methods for Treating CNS Disorders Methods Compositions and Methods for Treating CNS Disorders Methods Compositions and Methods for Treating CNS Disorders Methods S2010 Compositions and Methods for Treating CNS Disorders Methods S2010 Compositions and Methods for Treating CNS Disorders Methods Compositions and Methods for Treating CNS Disorders Methods S2010 Compositions and Methods for Treating CNS Disorders Methods Compositions and Methods of Treating CNS Disorders Methods Compositions and Methods for Treating CNS Disorders Methods Compositions and Methods for Treating CNS Disorders EPIX DELAWARE, INC. Methods Compositions and Methods of Treating CNS Disorders Methods Compositions and Methods of Treating CNS Disorders EPIX DELAWARE, INC. Methods CNS Disorders EPIX DELAWARE, INC. Methods CNS Disorders EPIX DELAWARE, INC. Methods CNS Disorders EPIX DELAWARE, INC.		Morocco	6-Jun-2008	31013	31013	Abandoned	PCT	08100-0069/03	PRX-3140
Japan Theropyridinore Compounds and Methods of Treatment EPIX DELAWARE, INC. Japan Compositions and Methods for Treatment CNS Disorders Korea Theropyridinore Compounds and Methods of Treatment EPIX DELAWARE, INC. Korea Compositions and Methods for Treatment EPIX DELAWARE, INC. Korea Compositions and Methods for Treatment EPIX DELAWARE, INC. Methods Compositions and Methods for Treatment EPIX DELAWARE, INC. Methods EPIX DELAWARE, INC. Methods Compositions and Methods of Treatment EPIX DELAWARE, INC. Methods EXECUTED Compositions and Methods for Treatment EPIX DELAWARE, INC. Methods Compositions and Methods for Treatment EPIX DELAWARE, INC. Methods Compositions and Methods for Treatment EPIX DELAWARE, INC. Methods Compositions and Methods for Treatment EPIX DELAWARE, INC. Theropyridinore Compounds and Methods of Treatment EPIX DELAWARE, INC.	_	Morocco	4-May-2007	29211	29866	Abandoned	PCT	08100-0069/01	PRX-3140
Japan Theopyridinoe Compounds and Methods of Treating CNS Disorders 5 Korea Thionopyridinoe Compounds and Methods for Treating CNS Disorders Korea Thionopyridinoe Compounds and Methods of Treating CNS Disorders Korea Compositors and Methods for Treating CNS Disorders Korea Compositors and Methods for Treating CNS Disorders Malaysia Compositors and Methods for Treating CNS Disorders Mexico ESCOTO Compositors and Methods of Treating CNS Disorders Mexico Compositors and Methods of Treating CNS Disorders Mexico Compositors and Methods of Treating CNS Disorders EPIX DELAWARE, INC. Mexico Compositors and Methods for Treating CNS Disorders Compositors and Methods for Treating CNS Disorders EPIX DELAWARE, INC.		Morocco	13-Nov-2006	28582	29451	Abandoned	PCT	00/6900-00180	PRX-3140
Japan Theopyridinore Compounds and Methods of Treatment EPIX DELAWARE, INC. Japan Compositions and Methods of Treatment Compounds and Methods of Treatment Compounds and Methods of Treatment Compounds and Methods of Treatment EPIX DELAWARE, INC. Korea Theopyridinore Compounds and Methods of Treatment EPIX DELAWARE, INC. Korea Compositions and Methods for Treating QNS Disorders Medico Segont Thieropyridinore Compounds and Methods of Treatment EPIX DELAWARE, INC. Medico Segont Thieropyridinore Compounds and Methods of Treatment EPIX DELAWARE, INC. Medico Segont Compositions and Methods for Treating CNS Disorders EPIX DELAWARE, INC.		Mexico				Unfiled	DIV	08100-0069/04	PRX-3140
Japan Theropyridinore Compounds and Methods of Treatment EPIX DELAWARE, INC. Japan Compositions and Methods for Treating CNK Disorders Korea Thieropyridinore Compounds and Methods of Treatment EPIX DELAWARE, INC. Korea Compositions and Methods of Treatment EPIX DELAWARE, INC. Maleysia Compositions and Methods for Treatment EPIX DELAWARE, INC. Methods Compositions and Methods for Treatment EPIX DELAWARE, INC.		Mexico	9-May-2008	277873	MX/a/2011/012986	Issued	PCI	08100.0069-04223	PRX-3140
Japan Theropyridinore Compounds and Methods of Treatment EPIX DELAWARE, INC. Japan Compositions and Methods for Treating CNIS Disorders Korea Theropyridinore Compounds and Methods of Treatment EPIX DELAWARE, INC. Korea Compositions and Methods for Treating CNIS Disorders Korea Compositions and Methods for Treating CNIS Disorders Compositions and Methods for Treating CNIS Disorders Compositions and Methods for Treating CNIS Disorders	Thienopyridinone	Mexico	6-Oct-2005		MX/a/2007/004230	Abandoned	PCI	08100-0069/01	PRX-3140
Japan Theropyridinore Compounts and Methods of Treatment EPIX DELAWARE, INC. Japan Compositions and Methods for Treating CNIS Disorders Korea Theropyridinore Compounds and Methods of Treatment Korea Compositions and Methods of Treatment Korea Compositions and Methods for Treatment EPIX DELAWARE, INC.	Compositions and	Malaysia	9-May-2008		PI 2008 1531	Abandoned	ORD	08100-0069/03	PRX-3140
Japan Theropyridinore Compounds and Methods of Treatment EPIX DELAWARE, INC. Japan Compositions and Methods for Treating CNS Disorders Konea Theropyridinone Compounds and Methods of Treatment EPIX DELAWARE, INC.	Compositions and	Korea	9-Jun-2008		10-2008-7013812	Abandoned	PCT	08100-0069/03202	PRX-3140
Japan Theropyridinore Compounds and Methods of Treatment EPIX DELAWARE, INC. Japan Compositions and Methods for Treating CNS Disorders Korea Theropyridinore Compounds and Methods of Treatment	Thienopyridinone	Korea	6-Oct-2005		10-2007-7008043	Abandoned	PCT	08100-0069/01202	PRX-3140
Japan Theropyridinore Compounds and Methods of Treatment EPIX DELAWARE, INC. Japan Compositions and Methods for Treating CNS Disorders	Thienopyridinone	Korea .	16-May-2005	10-1216296	10-2006-7023904	ssued	PCT	08100-0069/00202	PRX-3140
Japan Thieropyridinone Compounds and Methods of Treatment EPIX DELAWARE, INC.	Compositions and	Japan	9-May-2008		2008-540098	Abandoned	PCT	08100-0069/03195	PRX-3140
	Thienopyridinone	Japan	6-Apr-2007		2007-535801	Abandoned	PCT	08100-0069/01	PRX-3140
Japan Thisnopyridinone Compounds and Nethods of Treatment	Thienopyridinone	Japan	15-Nov-2006	4897683	2007-527345	Issued	PCT	08100-0069/00	PRX-3140
-Apr-2008 Israel Compositions and Methods for Treating CNS Disorders EPIX DELAWARE, INC.	Compositions and	srael	30-Apr-2008		191168	Abandoned	PCT	08100-0069/03	PRX-3140

Coltrological			munical in conservation and an english make some processor of the second	56-080-1250	0.8.	7661-10H-01	3241301	07/868,072	Inactive	CON	20/1/100-00190	KAMO
CHANCHORN COL. Col. Stands CHANCO COL. CHANCE CHAN			Memor for Selectively increasing the Ratio of Single Wayor Components of Anthropic A (19686 Complex		U.S.	2-May-1990	70,700	07/519,333	Abandoned	CON	08100-0077/01	RAMO
WWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWW			Method for Selectively increasing the natio of single wayor components of Artibotom At 1999 Complex		U.S.	10-Sep-1987		07/095,364	Abandoned	ORD	08100-0077/00	RAMO
1000/00000 70,			Mountain Constant Instrument the Date of Chiefe Moise Companions of Anthropis A 18688 Complex	29-Jun-1988	South Atrica	10-Sep-198/	0110110	87/6773	Abandoned	ORD	08100-007700	KAMO
000-0000000 CM bund USM_ALL VERYING 14/321 CAR22500 CUL Description Change of Internet Auto-Internet Auto-Internet <th< th=""><th></th><th></th><td>Method for Selectively Increasing the Ratio of Single Major Components of Antibiotic A/16686 Complex</td><td>20 111 4000</td><td>Noise .</td><td>1000-1007</td><td>97/6773</td><td>07-10010</td><th>Apandoned</th><td>S</td><td>00100 007700</td><td>SAMO O</td></th<>			Method for Selectively Increasing the Ratio of Single Major Components of Antibiotic A/16686 Complex	20 111 4000	Noise .	1000-1007	97/6773	07-10010	Apandoned	S	00100 007700	SAMO O
00 000000000 CON based USAN, BASE VARIATE LANCESTANDO LANCESTANDO CONTRICTION CANADADA LANCESTANDO CONTRICTION CANADADA CONTRICTION			Method for Selectively Increasing the Ratio of Single Major Components of Antibiotic A/16686 Complex	20-Mar-1997	Kores	10-Sep-1087	113262	87.10010	Abandanad	3	08100-0077/00	RAMO
2010-200901 DD Interest 10000561 Column Colum			Method for Selectively Increasing the Ratio of Single Major Components of Antibiotic A/16886 Complex	12-Dec-1997	Japan	11-Sep-1987	2728406	226736/87	Expired	ORD	08:00-0077/00	RAMO
Mathematic March			Method for Selectively Increasing the Retio of Single Major Components of Antibiotic A/16886 Complex	23-May-1993	Israel	3-Mar-1992	101132	101132	Expired	DIV .	08100-0077/01	RAMO
Controlledies Control Control			Method for Selectively Increasing the Ratio of Single Major Components of Antibiotic A/16686 Complex	20-Jul-1993	Israel	2-Sep-1987	83736	83736	Expired	ORD	08100-0077/00	RAMO
\$1,00,000000000000000000000000000000000			Method for Selectively increasing the Ratio of Single Major Components of Antibiotic A/16686 Complex	10-Jun-1994	Ireland	10-Sep-1987	60223	2421/87	Abandoned	ORD	08100-0077/00	RAMO
1010-040805 CDI			Method for Selectively increasing the Ratio of Single Major Components of Antibiotic A/16686 Complex	25-May-1989	Hungary	10-Sep-1987	198229	4033/87	Expired	ORD	08100-0077/00	RAMO
2010-2010/10/15/15/15/15/15/15/15/15/15/15/15/15/15/			Method for Selectively increasing the Ratio of Single Major Components of Antibiotic A/16686 Complex	24-Mar-1993	Europe	3-Sep-1987	259780	87112861.7	Expired	ORO	08100-0077/00	RAMO
1000-000000000 CO			Method for Selectively Increasing the Ratio of Single Major Components of Antibiotic A/16886 Complex	21-Jun-1993	Denmark	4-Sep-1987	166.628	4617/87	Expired	ORB	08100-0077/00	RAMO
1985/2007/2007/2007/2007/2007/2007/2007/200			Method for Selectively Increasing the Ratio of Single Major Components of Antibiotic A/16886 Complex	26-May-1992	Canada	10-Sep-1987	1301689	546553	Expired	ORD	08100-0077/00	RAMO
2000/000001 Cot December Cot District Cot District Cot District Dist	IRMACEUTICALS CORPORATION	OSCIENT PHAR	Use of Ramoplanin to Treat Diseases Associated with the Use of Antibiotics		U.S.	10-Sep-2009		12/557,099	Abandoned	CON	08100-0076/03	RAMO
2010-2008501 CDV Internat 1908-054	IRMACEUTICALS CORPORATION	OSCIENT PHAR	Use of Ramoplanin to Treat Diseases Associated with the Use of Antibiotics		U.S.	3-Oct-2007		11/906,750	Abandoned	DIV	08100-0076/02	RAMO
	RMACEUTICALS CORPORATION	OSCIENT PHAR	Use of Ramoplanin to Treat Diseases Associated with the Use of Antibiotics		U.S.	20-Sep-2006		11/524,053	Abandoned	CON	08100-0076/01	RAMO
Control Cont	IRMACEUTICALS CORPORATION	OSCIENT PHAR	Use of Ramoplanin to Treat Diseases Associated with the Use of Antibiotics	08-Jan-2008	U.S.	5-Jun-2003	7317001	10/454,998	Issued	ORD	08100-0076/00	RAMO
CHICACOMONICI COPY Instead 10565,04 CHICACOMONICI COPY Instead 10565,04 CHICACOMONICI COPY Instead 10565,05 CHICACOMONICI COPY CHICACOMONICI COPY CHICACOMONICI CHICACOMON	RMACEUTICALS CORPORATION	OSCIENT PHAR	Use of Ramoplanin to Treat Diseases Associated with the Use of Antibiotics		PCT	5-Jun-2005		PCT/US03/17709	Completed	ORD	08100-0076/00	RAMO
Applications Application	RMACEUTICALS CORPORATION	OSCIENT PHAR	Use of Ramoplanin to Treat Diseases Associated with the Use of Antibiotics	8/13/2013	Canada	6-Dec-2004		2488803	Issued	PCT	08100-0076/00	RAMO
2010-2003/201 Col. Interest 10555_014 10555_015 1055_015_015 1055_015_015 1055_015 1055_015 1055_015 1055_015 1055_015 1055_015 1055_015 1055_015 1055_015 1055_015 1055_015 1055_015 1055_015 1055_015 1055_015 1055_015 1055_015_015 1055_015_015 1055_015_015_015_015_015_015_015_015_015	OTHERAPEUTICS, INC.	NANO	Methods for Preventing Gram-Positive Bacteremias		U.S.	29-Apr-2009		12/387,226	Pending	CON	08100-0075/03	RAMO
2010-000000 O/O Internet 1005.54 1005.54 174878 174878 1749			Methods for Preventing Gram-Positive Bacteremias		U.S.	2-Sep-2008		12/231,332	Abandoned	CON	08100-0075/02	RAMO
Reconstruction Column Co			Method for Treating and Preventing Gram-Positive Bacteremias		U.S.	8-Nov-2007		11/983,803	Abandoned	CON	08100-0075/01	RAMO
2010-0009000 COV Essard 10955_C44 10955_C44			Methods for Preventing Gram-Positive Bacteremias		U.S.	4-Sep-2003		10/655,185	Abandoned	OR OR	08100-0075/00	RAMO
2010-0009901 CDN Issaed 110595_044 110595_049 10.000 10.000 10.000 10.000 10.000 10.000 10.000 10.000 10.000 10.000 10.000 10.000 10.000 10.000 10.000 10.00000 10.00000 10.00000 10.00000 10.00000 10.00000 10.00000 10.00000 10.00000 10.00000 10.00000 10.00000 10.00000 10.00000 10.000000 10.000000 10.000000 10.000000 10.000000 10.0000000 10.0000000 10.00000000 10.000000000 10.0000000000	RMACEUTICALS CORPORATION	OSCIENT PHAR	Methods for reducing or preventing transmission of nosocomial pathogens		U.S.	1-Oct-2009		12571,789	Abandoned	CON	08100-0074/02	RAMO
1.000.0000000 0.00 1.0000000000 0.00 1.0000000000			Methods for reducing or preventing transmission of nosocomial pathogens		U.S.	2-Feb-2009		12/322,420	Abandoned	CON	08100-0074/01	RAMO
Decided Decide			Methods for reducing or preventing transmission of nosocomial pathogens		U.S.	26-Apr-2004		10/832,965	Abandoned	ORD	08100-0074/00	RAMO
Delition (1999) Delition Delition (1999)	RMACEUTICALS CORPORATION	OSCIENT PHAR	Methods for reducing or preventing transmission of nosocomial pathogens		PCT	26-Apr-2004		PCT/US04/012856	Completed	ORD	08100-0074/00	RAMO
	RMACEUTICALS CORPORATION	OSCIENT PHAR	Methods for reducing or preventing transmission of noscoomial pathogens		Canada	25-Oct-2005		2523573	Abandoned	PCT	08100-0074/00	RAMO
26100-0058901 CON Issued 10855,544 748735 30-5ap-2004 U.S. 05-6ab-2005 Thérropyridione Compounds and Methods of Treatment NANOTHERAPEUTICS, INC.	OTHERAPEUTICS, INC.	NANO	Bicyclic Compounds and Methods of Making and Using Same		United Kindom		2,445,877	9768573.9	ssued		08100-0073/00	PRX-3140
2010-0005901 CRU Instanct International Compounds and Methods of Treatment International Compounds	OTHERAPEUTICS, INC.	NANO	Bicyclic Compounds and Methods of Waking and Using Same		yledi		2,445,877	9768573.9	ssued		08100-0073/00	PRX-3140
Decided Deci	OTHERAPEUTICS, INC.	NANO	Bicyclic Compounds and Methods of Making and Using Same		Germany		2,445,877	9768573.9	ssued		08100-0073/00	PRX-3140
Decided Deci	OTHERAPEUTICS, INC.	NANO	Bicyclic Compounds and Methods of Making and Using Same		France		2,445,877	9768573.9	ssued		08100-0073/00	PRX-3140
ORT ORT	OTHERAPEUTICS, INC.	NANO	Bicyclic Compounds and Methods of Making and Using Same	7/23/2014	Europe	1-Jul-2011	2,445,877	9768573.9	ssued	ORD	08100-0073/00155	PRX-3140
ORT ORT	OTHERAPEUTICS, INC.	NANO	Bicyclic Compounds and Methods of Making and Using Same		U.S.	15-Dec-2011		13/326,836	Abandoned	Νď	08100-0073-01000	PRX-3140
ORT ORT	OTHERAPEUTICS, INC.	NANO	Bioyclic Compounds and Methods of Making and Using Same	2/14/2012	U.S.	3-Dec-2009	8,114,894	12/630,468	ssued	ORD	08100-0073/00000	PRX-3140
DRD DRD			Bicyclic Compounds and Methods of Making and Using Same		PCT	3-Dec-2009		PCT/US09/66589	Pending	ORD	08100-0073/00	PRX-3140
ORD Issued 10955,434 748736 30-5ep-2004 U.S. 17-Eeb-2005 Trienropyridinone Compounds and Methods of Treatment NANOTHERAPEUTICS, INC. 06100-006907 CON Issued 10960/189 7407966 7-Oct-2004 U.S. 05-Aug-2008 Thienropyridinone Compounds and Methods of Treatment NANOTHERAPEUTICS, INC. 06100-006907 ORD Issued 11071/199 7798765 10-Nov-2006 U.S. 18-Aug-2009 Thienropyridinone Compounds and Methods of Treatment NANOTHERAPEUTICS, INC. 06100-006907 ORD Issued 11271/199 7798765 10-Nov-2006 U.S. 06-Oct-2009 U.S. 06-Oct-2009 Ord propositions and Methods of Treatment NANOTHERAPEUTICS, INC. 06100-006907 ORD Abandoned 112012, 1159 7982765 10-Nov-2006 U.S. 06-Oct-2009 Ord propositions and Uses Research Ord propositions and Uses Research Ord propositions and Methods of Treatment NANOTHERAPEUTICS, INC. Ord propositions and Methods of Treatment NANOTHERAPEUTICS, INC. Ord propositions and Methods of Treatment Ord Propositions Ord			Compositions and Methods for Treating CNS Disorders		Viet Nam	5-May-2008		1-2008-01052	Abandoned	PCT	08100-0069/03	PRX-3140
	PIX DELAWARE, INC.	EPI.	Thienopyridinone Compounds and Methods of Treatment		Viet Nam	4-Apr-2007		1/2007/00726	Abandoned	PCT	08100-0069/01	PRX-3140
ORTIO_ORBINO_ORBON_ORD_ ORD_ Issued 10,955,434 748736 30,58p-2004 U.S. 10,Feb-2009 Thieropyridinore Compounds and Methods of Treatment NANOTHERAPEUTICS, INC. 08100-006907 CON Issued 11,0580,789 7407966 7,0d-2004 U.S. 05,4ug-2008 Thieropyridinore Compounds and Methods of Treatment NANOTHERAPEUTICS, INC. 08100-006907 ORD_ Issued 11,7219,019 759235 O. O. O. O. O. O. O. O	PIX DELAWARE, INC.	EPI.	Thienopyridinone Compounds and Methods of Treatment		Viet Nam	17-Nov-2006		1-2006-01897	Abandoned	PCT	08100-0069/00	PRX-3140
		NANO	Compositions and Methods for Treating CNS Disorders		U.S.	30-Sep-2009	-	12/570,510	Abandoned	DIV	08100-0069/06	PRX-3140
08(100-006900 ORD Issued 10,955,434 748736 30,5ep-2004 U.S. 10,Feb-2009 Thieropyridinore Compounds and Methods of Treatment AMAINTHERAPEUTICS, INC. 08(100-006901 CON Issued 10,950,759 7407965 7-0ct-2004 U.S. 05,4ug-2008 Thieropyridinore Compounds and Methods of Treatment AMAINTHERAPEUTICS, INC. 08(100-006902 DN Issued 11/259,042 7578211 8-Nov-2005 U.S. 18,4ug-2009 Thieropyridinore Compounds and Methods of Treatment AMAINTHERAPEUTICS, INC. 08(100-006902 ORD Issued 11/271,019 759255 10,4vov-2005 U.S. 06-0ct-2009 Compositions and Methods for Treatment AMAINTHERAPEUTICS, INC. 08(100-006902 ORD Abandoned 11/259,042 759255 10,4vov-2005 U.S. 06-0ct-2009 Compositions and Methods for Treatment AMAINTHERAPEUTICS, INC.		NANO	Thienopyridinone Compounds and Methods of Treatment	7/19/2011	U.S.	24-Dec-2008	7,982,040	12/343,818	Issued	CON	08100-0069/05	PRX-3140
08/100-006900 ORD Issued 10,955,434 748735 30-Sep-2004 U.S. 10-Feb-2009 Thieropyridinore Compounds and Methods of Treatment AMANTHERAPEUTICS, INC. 08/100-006901 CON Issued 10,950,759 7407955 7-Cot-2004 U.S. 05-Aug-2008 Thieropyridinore Compounds and Methods of Treatment AMANTHERAPEUTICS, INC. 08/100-006902 D/V Issued 11/259,042 7578211 8-Nov-2005 U.S. 16-Aug-2009 Thieropyridinore Compounds and Methods of Treatment AMANTHERAPEUTICS, INC. 08/100-006903 ORD Issued 11/275,019 758255 10-Nov-2005 U.S. 06-Oct-2009 Compositions and Methods for Treatment AMANTHERAPEUTICS, INC.		NANO	5-HT4 modulating compounds and uses thereor		U.S.	9-Nov-2006		11/595,806	Abandoned	ORD	08100-0069/04	PRX-3140
08/100-0069/07 ORD Issued 10/955,434 748736 30-Sep-2004 U.S. 10-Feb-2009 Trienropyridinore Compounds and Methods of Treatment MANOTHERAPEUTICS, INC. 08/100-0069/07 CON Issued 10/950/759 7407965 7-Cod-2004 U.S. 05-Aug-2008 Trienropyridinore Compounds and Methods of Treatment NANOTHERAPEUTICS, INC. 08/100-0069/07 D/V Issued 11/259,042 7578211 8-Nov-2005 U.S. 18-Aug-2009 Trienropyridinore Compounds and Methods of Treatment NANOTHERAPEUTICS, INC.		NANO	Compositions and Methods for Treating CNS Disorders	06-Oct-2009	U.S.	10-Nov-2005	7598265	11/271,019	Issued	ORD	08100-0069/03	PRX-3140
08/100-006900 ORD Issued 10/955_434 748735 30-Sep-2004 U.S. 10-Feb-2009 Triesropyridinore Compounds and Methods of Treatment NAMOTHERAPEUTICS, INC. 08/100-006901 CON Issued 10/960/759 7407965 7-Oct-2004 U.S. 05-Aug-2008 Triesropyridinore Compounds and Methods of Treatment NAMOTHERAPEUTICS, INC.		NANO	Thieropyridinone Compounds and Methods of Treatment	18-Aug-2009	U.S.	8-Nov-2005	7576211	11/269,042	Issued	N/G	08100-0069/02	PRX-3140
06:100-0069/00 ORD Issued 10/855.43.4 7488736 30-Sep-2004 U.S. 10-Feb-2009 Thiempsylidinone Compounds and Methods of Treatment		NANO	Thieropyridinone Compounds and Methods of Treatment	05-Aug-2008	U.S.	7-0ct-2004	7407966	10/960,769	Issued	CON	08100-0069/01	PRX-3140
	OTHERAPEUTICS, INC.	NANO	Thenopyridinone Compounds and Methods of Treatment	10-Feb-2009	U.S.	30-Sep-2004	7488736	10/955,434	Issued	ORD	08100-0069/00	PRX-3140

injectable Formisistons Containing Remoplerin ORCIENT PHARMACEUTICALS OCRPORATION ALVI GUANYLITANISTERASE ASSAYS VION PHARMACEUTICALS, INC. Combination therapy comprising deretazine COMPRIANACEUTICALS, INC. VION PHARAMACEUTICALS, IN	Combination transpy comprising development Combination therapy comprising development Phosphate-bearing Produngs of Sulfonyl Hydrazin	20-Oct-2009 88/2012 88/2012 88/2012 88/2012 88/2012 88/2012 9 9 9 9-14-2004 30-14sy-2004 30-14sy-2004 37/21/2012	France France Hong Kong PCT U.S. Europa France Germany Spain Great Britain Hong Kong India Japan Mexico PCT Singapore U.S. U.S. U.S. U.S. Canada China Conada	11-Feb-2008 55-Mar-2005 55-Mar-2005 55-Sep-2006 19-Apr-2007 13-Jun-2007 13-Jun-2007 13-Jun-2007 2-Mar-2007 2-Mar-2007 2-Mar-2007 2-Mar-2007 2-Mar-2007 2-Mar-2007 2-Mar-2007 2-Mar-2007 2-Mar-2008 21-Sep-2005	1793823 1793823 1793823 218878 218678 130599 7405317 2005288833 2005288833	5812794.5 5812794.5 7.110820.8 7710KOLNE/2007 2007-525910 9910422 PCT/US2005/033641 200701898-1 11/202.262 11/208.267 2005288833 2575289 2,0058E-11 2525991 2,0048E-11 2,0048E-11	Abandoned Completed Abandoned Issued Abandoned Issued Abandoned Issued Abandoned Lapsed Abandoned Lapsed			CLOR/ONRIGIN CLOR/ONRIGIN CLOR/ONRIGIN CLOR/ONRIGIN CLOR/ONRIGIN
to induce muosal immunity trazines as Hypoxia-selective Antineoplastic Agents	Combination therapy comprising door Phosphate-bearing Produngs of Sulfic			11-Feb-2008 25-Mar-2005 15-Sep-2006 19-Apr-2007 13-Jun-2007 13-Jun-2007 13-Jun-2007 13-Jun-2007 2-Mar-2007 2-Mar-2007 2-Mar-2007 2-Mar-2007 2-Mar-2007 2-Mar-2007 2-Mar-2007 2-Mar-2007 2-Mar-2008 21-Sep-2005 21-	1798823 1798823 218878 218878 218689 7405317 2005286833 2005286833	5812794.5 5812794.6 7110820.8 7710KOLNP2007 2007.525810 9910422 PC71U52005003841 11032.252 12080.387 200588433 2515269 2,0038E41 2,0038E41 2,0038E41 2,0038E41	Abandoned Completed Abandoned Issued Abandoned Issued Abandoned Issued Abandoned Abandoned Abandoned			CLOR/ONRIGIN CLOR/ONRIGIN CLOR/ONRIGIN CLOR/ONRIGIN CLOR/ONRIGIN
to induce mucosal immunity trazines as Hypoxia-selective Antineoplastic Agents	Combination therapy comprising dom Phosphate-bearing Prodrugs of Sulfe			11-Feb-2008 25-Mar-2005 15-Sep-2006 19-Apr-2007 13-Jun-2007 13-Jun	1798823 1798823 218878 218878 218878 2180599 7405317 2005288833	5812794.5 5812794.5 5812794.6 7710820.8 7710820.8 770KOLNP2007 2007-52810 9910422 PC71/U\$2008/033941 1/0202/522 1/0803.97 2005286833 20058E-41 2555689 20058E-41	Abandoned Completed Abandoned Issued Abandoned Issued Abandoned Issued Abandoned Abandoned Abandoned Abandoned			CLOR/ONRIGIN CLOR/ONRIGIN CLOR/ONRIGIN CLOR/ONRIGIN
to induce mucosal immunity trazines as Hypoxia-selective Antineoplastic Agents	Combination therapy comprising dom Phosphate-bearing Prodrugs of Sulfic			11-Feb-2008 55-Sep-2006 15-Sep-2006 19-Apr-2007 13-Jun-2007 13-Jun-2007 13-Jun-2007 13-Jun-2007 13-Jun-2007 2-Mar-2007 2-Mar-2007 2-Mar-2007 2-Mar-2008 21-Sep-2005 21-Sep-2005 21-Sep-2006 21-Sep-2006 21-Sep-2006 21-Sep-2006 21-Sep-2008	1793823 1793823 218878 218878 130599 7405317 2005286833	5812794.5 5812794.5 5812794.6 7110820.8 7710KOLNP/2007 2007-532610 9910422 PCT/IJS2005/033541 200701699-1 110202/262 12000387 2005/268033 25/57289 20068E-41	Abandoned Completed Abandoned Issued Abandoned Issued Abandoned Issued Abandoned			CLOR/ONRIGIN CLOR/ONRIGIN CLOR/ONRIGIN
to induce mucosal immunity to induce mucosal immunity to induce sa Hypoxia-salective Antimeoplastic Agents frazines as Hypoxia-salective Antimeoplastic Agents	Combination therapy comprising doin Phosphate-bearing Prodrugs of Sulfic			11-Feb-2008 25-Mar-2005 15-Sep-2006 19-Apr-2007 13-Jun-2007 13-Jun-2007 13-Jun-2007 13-Jun-2007 2-Mar-2007 2-Mar-2007 2-Mar-2007 2-Mar-2007 2-Mar-2007 2-Mar-2005 21-Sep-2005 21-Sep-2005 21-Sep-2005 21-Sep-2005 21-Sep-2005	1793823 1793823 218878 218878 219529 1305288833 2005288833	5812794.5 5812794.5 7110820.8 7710KOLNE/2007 2007-525010 9910422 PC710452005033541 200701699.1 11232,262 112080,267 2005288833 2575569	Abandoned Completed Abandoned Issued Abandoned Issued Abandoned Issued Abandoned			CLOR/ONRIGIN CLOR/ONRIGIN
to induce muosal immunity to induce muosal immunity to induce muosal immunity to induce muosal immunity trazines as Hypoxia-selective Antineoplastic Agents	Combination therapy comprising door Phosphate-bearing Produngs of Sulfic			11-Feb-2008 25-Mar-2005 15-Sep-2006 15-Sep-2006 19-Apr-2007 13-Jun-2007 13-Jun-2007 13-Jun-2007 13-Jun-2007 2-Mar-2007	1798823 1798823 218878 218878 218878 7405317	5812794.5 5812794.5 7110820.8 770KOLNP2007 2007.523610 9910422 PCT/US20050038641 2007016889-1 11032.252 12080.337	Abandoned Completed Abandoned Issued Abandoned issued			CLOR/ONRIGIN
to induce muosal immunity trazines as Hypoxia-selective Antineoplastic Agents	Combination therapy comprising dom Phosphate-bearing Prodrugs of Sulfic			11Feb-2008 25-Mar-2005 15-Sep-2006 19-Apr-2007 13-Jun-2007 13-Jun-	1798823 1798823 218878 218878 130589 7405317	5812784.5 5812784.6 7110820.8 7710820.18 770KOLIMP2007 2007-52810 9910422 PC7/1852005/033841 200701699-1 110202.582 12080.587	Abandoned Completed Abandoned Issued Abandoned	ORD	$\dashv \dashv$	CLOR/ONRIGIN
to induce mucosal immunity tazines as Hypoxia-selective Antineoplastic Agents trazines as Hypoxia-selective Antineoplastic Agents	Combination therapy comprising dom Phosphate-bearing Prodrugs of Sulfe			11-Feb-2008 55-Sep-2006 15-Sep-2006 19-Apr-2007 13-Jun-2007 13-Jun-2008 12-Jun-2008 12-Jun-2008 12-Jun-2008 13-Jun-2008	1793823 1793823 218878 218878 130599 7405317	5812794.5 5812794.5 5812794.5 7110820.8 770KCLHP/2007 2007-532610 9910422 PC/T/US2005003841 200701689-1 11/232.252	Abandoned Completed Abandoned Issued	ORD	-	
to induse mucosal immunity to induse mucosal immunity to induse mucosal immunity to induse mucosal immunity tazines as Hypoxia-selective Antineoplastic Agants trazines as Hypoxia-selective Antineoplastic Agants	Combination therapy comprising door Phosphate-bearing Prodrugs of Sulfic			11-Feb-2008 25-Mar-2005 16-Sep-2006 19-Apr-2007 13-Jun-2007 13-Jun-2007 13-Jun-2007 13-Jun-2007 2-Mar-2007	1793823 1793823 1793823 130699	5812794.5 5812794.5 7110820.8 7710KDLNP/2007 2007.532610 9910422 PCT/US2005/033541 200701698-1	Abandoned Completed Abandoned			CLOR/ONRIGIN
to induce mucosal immunity to induce mucosal immunity to induce mucosal immunity lazines as Hypoxie-selective Antineoplastic Agents trazines as Hypoxie-selective Antineoplastic Agents	Combination therapy comprising door Phosphate-bearing Produngs of Sulfic			11-Feb-2008 25-Mar-2005 15-Sep-2006 19-Apr-2007 13-Jun-2007 13-Jun	1793823 1793823 218878	5812794.5 5812794.5 7110820.8 710KOLN-72007 2007-532610 9910422 PC710822005033841	Abandoned Completed	ORD	08100-0093/00	CLOR/ONRIGIN
to induce muosal immunity to induce muosal immunity to induce muosal immunity to induce muosal immunity trazines as Hypoxia-selective Antineoplastic Agents	Combination therapy comprising door Phosphate-bearing Producys of Sulfic			11-Feb-2008 25-Mar-2005 15-Sep-2006 19-Apr-2007 19-Jun-2007 19-Jun	1793823	5812794.5 5812794.5 7110820.8 770KOLNP2007 2007-532810 9910422	Abandoned	ORD	08100-0093/00	CLOR/ONRIGIN
to induce mucosal immunity to induce mucosal immunity to induce mucosal immunity trazines as Hypoxia-selective Antineoplastic Agents	Combination therapy comprising dom Combination therapy comprising dom Combination therapy comprising dom Combination therapy comprising dom Combination therapy comprising dow Combination therapy comprising dow Phosphate-bearing Prodrugs of Sulfic			11-Feb-2008 25-Mar-2005 15-Sep-2006 19-Apr-2007 13-Jun-2007 13-Jun-2007 13-Jun-2007 13-Jun-2007 13-Jun-2007 2-Mar-2007 2-Mar-2007	1793823	5812794.5 5812794.5 7110820.8 770KOLNP/2007 2007-532810		PCT	08100-0093/00	CLOR/ONRIGIN
to induce mucossi immunity to induce mucossi immunity to induce mucossi immunity trazines as Hypoxia-selective Antineoplastic Agents	Combination therapy comprising dom Combination therapy comprising dow Phosphate-bearing Prodrugs of Sulfic			11-Feb-2008 25-Mar-2005 15-Sep-2006 19-Apr-2007 13-Jun-2007 13-Jun-2007 13-Jun-2007 13-Jun-2007 2-Mar-2007	1793823	5812794.5 5812794.5 7110820.8 770KOLNPI2007	ssued	PCT	08100-0093/00	CLOR/ONRIGIN
to induce mucosal immunity to induce mucosal immunity to induce mucosal immunity to induce mucosal immunity tazines as thypoxia-selective Antineoplastic Agents tazines as thypoxia-selective Antineoplastic Agents trazines as thypoxia-selective Antineoplastic Agents	Combination therapy comprising donal Combination therapy comprising don			11-Feb-2008 25-Mar-2005 15-Sep-2006 19-Apr-2007 13-Jun-2007 13-Jun-2007 13-Jun-2007 13-Jun-2007	1793823	5812794.5 5812794.5 7110820.8	Abandoned	PCT	08100-0093/00187	CLOR/ONRIGIN
to induce muossi immunity to induce muossi immunity lazines as Hypoxia-salactive Antineoplastic Agents trazines as Hypoxia-salactive Antineoplastic Agents trazines as Hypoxia-salactive Antineoplastic Agents trazines as Hypoxia-salactive Antineoplastic Agents frazines as Hypoxia-salactive Antineoplastic Agents	Combination therapy comprising door Phosphate-bearing Produtage of Sulfic Phosphate-bearing Produtage of Sulfic Phosphate-bearing Produtage of Sulfic			11-Feb-2008 25-Mar-2005 15-Sep-2006 19-Apr-2007 13-Jun-2007 13-Jun-2007 13-Jun-2007	1793823	5812794.5 5812794.5	Abandoned	PCT	08100-0093/00178	CLOR/ONRIGIN
to induce muosal immunity to induce muosal immunity trazines as Hypoxia-selective Antineoplastic Agents	Combination treately comprising don Combination therapy comprising don Phosphate-bearing Prodrugs of Sulfe Phosphate-bearing Prodrugs of Sulfe Phosphate-bearing Prodrugs of Sulfe Phosphate-bearing Prodrugs of Sulfe			11-Feb-2008 25-Mar-2005 15-Sep-2006 19-Apr-2007 13-Jun-2007 13-Jun-2007	1130000	5812794.5	Granted		08100.0093/00155	CLOR/ONRIGIN
to induce muosasi immunity to induce muosasi immunity razines as Hypoxia-selective Antineoplastic Agents razines as Hypoxia-selective Antineoplastic Agents	Combination transpy comprising don Combination therapy comprising don Phosphate-bearing Prodrugs of Sulfe Phosphate-bearing Prodrugs of Sulfe Phosphate-bearing Prodrugs of Sulfe			11-Feb-2008 25-Mar-2005 15-Sep-2006 19-Apr-2007 13-Jun-2007	1702822		Abandoned		08100.0093/00155	CLOR/ONRIGIN
to induse mucesal immunity to induse mucesal immunity trazines as Phypoxia-selective Antineoplastic Agents trazines as Phypoxia-selective Antineoplastic Agents	Combination treated complising don Combination therapy comprising don Phosphate-bearing Produgs of Sulfic			11-Feb-2008 25-Mar-2005 15-Sep-2006 19-Apr-2007 13-Jun-2007	1793823	5812794.5	Granted		08100.0093/00155	CLOR/ONRIGIN
to induse mucesal immunity to induse mucesal immunity transfer and tra	Combination trainty comprising don Combination therapy comprising don Phosphate-bearing Produgs of Sulfa.		+++++	11-Feb-2008 25-Mar-2005 15-Sep-2006 19-Apr-2007	1793823	5812794.5	Granted		08100-0093/00155	CLOR/ONRIGIN
nin duse muossal immunity	Combination therapy comprising don			11-Feb-2008 25-Mar-2005 15-Sep-2006	1793823	5812794.5	Granted	PCT	08100-0093/00155	CLOR/ONRIGIN
nin duse muosal immunity	Combination therapy comprising don Combination therapy comprising don Combination therapy comprising don Combination therapy comprising don	9		11-Feb-2008 25-Mar-2005	7605137	10/593,217	Issued	PCT	08100-0087/00000	CLOR
to induse mucosal immunity	Combination therapy comprising don Combination therapy comprising don	9	+++	11-Feb-2008		PCT/US2005/010152	Completed	ORD	08100-0087/00	CLOR
to induse mucosal immunity	Combination therapy comprising don		France			8101520.9	Abandoned	PCI	08100-0087/00	CLOR
to induse mucesal immunity	Condition metapy complising con		imit		1804816	5745357.3	Granted		08100-0087/00155	CLOR
nin to induse mucessi immunity			Vieti		1804816	5745357.3	Granted		08100-0087/00155	CLOR
nin to induse muossal immunity	Combination therapy comprising cloretazine		Spain		1804816	5745357.3	Abandoned		08100-0087/00155	CLOR
nin to induce mucossi immunity	Combination therapy comprising clore	5	Great Britain		1804816	5745357.3	Granted		08100-0087/00155	CLOR
nin to induce mucosal immunity	Combination therapy comprising doretazine		Germany		6.02005E+11	5745357.3	Granted		08100-0087/00155	CLOR
nin to induce mucosal immunity	Combination therapy comprising doretazine		Europe	26-Apr-2007	1804816	5745357.3	ssued	PCT	08100-0087/00155	CLOR
nin to induce mucosal immunity	Combination therapy comprising cloretazine		China	22-Sep-2006		2.0058E+12	Abandoned	PCT	08100-0087/00	CLOR
e to induce mucosal immunity	ALKYLGUANYLTRANSFERASE ASSAYS	25-Sep-2007	U.S.	9-Mar-2006	7273714	11/373,623	Issued	ORD	08100-0086/00	CLOR
	Oral delivery of vaccine to the large in		PCT				Unfiled	PCT	08100-0085/00	VION
_	Injectable Formulations Containing Ramoplanin	13-Apr-2004	U.S.	30-Jan-2001	6720305	09/744,247	Issued	PCT	08100-0079/00	RAMO
OSCIENT PHARMACEUTICALS CORPORATION	Antibiotic A/16686 Recovery Process	23-Jul-1996	U.S.	18-May-1995	5539087	08/444,808	Issued(Expired?)	CON	08100-0078/05	RAMO
	Antibiotic A/16686 Recovery Process		U.S.	16-Nov-1994		08/341,324	Abandoned	CON	08100-0078/04	RAMO
356	Antibiotic A/16686 Recovery Process		U.S.	1-Mar-1994		08/203,889	Abandoned	CON	08100-0078/03	RAMO
SSS	Antibiotic A/16686 Recovery Process		U.S.	4-Feb-1993		-475684	Abandoned	CON	08100-0078/02	RAMO
255	Antibiotic A/16686 Recovery Process		U.S.	27-Mar-1992		07/860,303	Abandoned	CON	08100-0078/01	RAMO
	Antibiotic A/16686 Recovery Process		U.S.	2-Nov-1990		07/608,426	Abandoned	ORD	08100-0078/00	RAMO
OSCIENT PHARMACEUTICALS CORPORATION	Antibiotic A/16686 Recovery Process		Korea	6-Nov-1990		10-1990-17892	Abandoned	ORD	08100-0078/05	RAMO
OSCIENT PHARMACEUTICALS CORPORATION	Antibiotic A/16686 Recovery Process	08-Sep-2000	Japan	7-Nov-1990	3107564	300035/90	Abandoned	ORD	08100-0078/05	RAMO
OSCIENT PHARMACEUTICALS CORPORATION	Antibiotic A/16686 Recovery Process	17-May-1995	Europe	2-Nov-1990	427142	90121040.1	Inactive	ORD	08100-0078/00	RAMO
OSCIENT PHARMACEUTICALS CORPORATION	Antibiotic A/16686 Recovery Process	12-Sep-2000	Canada	6-Nov-1990	2029408	2029408	Abandoned	ORD	08100-0078/05	RAMO
Method for Selectively Increasing the Ratio of Single Major Components of Antibiotic A15686 Complex OSCIENT PHARMACEUTICALS CORPORATION	Method for Selectively Increasing the	20-Jul-1999	U.S.	18-Dec-1997	5925550	08/993,729	Expired	CON	08100-0077/06	RAMO
	Method for Selectively Increasing the		U.S.	1-Jun-1995		08/457,607	Abandoned	CON	08100-0077/05	RAMO
Method for Selectively Increasing the Ratio of Single Major Components of Antibiotic A/16886 Complex	Method for Selectively Increasing the		U.S.	28-Jun-1994		08/267,094	Abandoned	CON	08100-0077/04	RAMO
Method for Selectively increasing the Ratio of Single Major Components of Antibiotic A/16886 Complex	Method for Selectively increasing the		U.S.	22-Oct-1993		08/141,426	Abandoned	C C C	08100-0077/03	RAMO

L	VION PHARMACEUTICALS, INC.	Prodrug Forms of Ribonucleotide Reductase Inhibitors 3-AP and 3-AMP		China	15-Nov-1999		98805148.6	Abandoned	PCT	08100-0091/00	TR
	VION PHARMACEUTICALS, INC.	Prodrug Forms of Ribonucleotide Reductase Inhibitors 3-AP and 3-AMP		Canada	12-Nov-1999		2290617	Abandoned	PCT	08100-0091/00	Z
	VION PHARMACEUTICALS, INC.	Prodrug Forms of Ribonucleotide Reductase Inhibitors 3-AP and 3-AMP		Brazil	16-Nov-1999		PI 09809633-8	Abandoned	PCT	08100-0091/00	TRI
	VION PHARMACEUTICALS, INC.	L	19-Apr-2001	Australia	9-Dec-1999	727848	74840/98	Abandoned	PCT	08100-0091/00	TRI
L		<u></u>	09-Feb-1999	U.S.	15-May-1997	5,869,676	08/856,559	Issued	ORD	08100-0090/00	TRI
L	VION PHARMACEUTICALS, INC.	Process for the synthesis of ribonucleotide reductase inhibitors of 3-AP and 3-AMP		Russia	14-Dec-1999		99126808	Abandoned	PCT	08100-0090/00	TRI
	VION PHARMACEUTICALS, INC.	Process for the synthesis of ribonucleotide reductase inhibitors of 3-AP and 3-AMP		PCT	14-May-1998		PCT/US98/009803	Completed	ORD	08100-0090/00	고
		L	12-May-2004	Mexico	12-Nov-1999	220367	9910427	Abandoned	PCT	08100-0090/00	TRI
	VION PHARMACEUTICALS, INC.	Process for the synthesis of ribonucleotide reductase inhibitors of 3-AP and 3-AMP		Korea	15-Nov-1999		10-1999-7010575	Abandoned	PCT	08100-0090/00	잼
	VION PHARMACEUTICALS, INC.	Process for the synthesis of ribonucleotide reductase inhibitors of 3-AP and 3-AMP		Japan	12-Nov-1999		10-549514	Abandoned	PCT	08100-0090/00	T _R I
	VION PHARMACEUTICALS, INC.	_	21-Nov-2003	Hong Kong	29-Jul-2000	HK1025567	104763.7	Abandoned	PCT	08100-0090/00	TRI
	VION PHARMACEUTICALS, INC.	Process for the synthesis of raconucleotide reductase inhibitors of 3-AP and 3-AMP		Europe	9-Dec-1999		98923414.1	Abandoned	PCT	08100-0090/00	TR:
	VION PHARMACEUTICALS, INC.	L	13-Aug-2003	China	15-Nov-1999	98805147.8	98805147.8	Issued	PCT	08100-0090/00	TR!
		Process for the synthesis of ribonucleotide reductase inhibitors of 3-AP and 3-AMP		Canada	12-Nov-1999		2289970	Abandoned	PCT	08100-0090/00	TR.
		Process for the synthesis of ribonucleotide reductase inhibitors of 3-AP and 3-AMP		Brazil	16-Nov-1999		PI9808810-6	Abandoned	PCT	08100-0090/00	TRI
		-	19-Apr-2001	Australia	14-May-1998	728165	199875714	Abandoned	EPC	08100-0090/00	TRI
		Cancer Treatment Comprising Triapine		China	16-Sep-2010		2.0101E+11	Abandoned	VIQ	08100-0089/01139	TR!
L	VION PHARMACEUTICALS, INC.	Cancer Treatment Comprising:Triapine		China	2-Jan-2004		2.0041E+11	Abandoned	ORD	08100-0089/00	IRI
	VION PHARMACEUTICALS, INC.	Compositions and Methods for Delivery of an Agent Using Attenuated Salmonella Containing Phage		U.S.	1-Mar-2004		10/790,586	Abandoned	CON	08100-0099/02	TAPET
	NANOTHERAPEUTICS, INC.	Compositions and Methods for Delivery of an Agent Using Attenuated Saimonella Containing Phage		U.S.	13-Feb-2002		10/076,117	Abandoned	CON	08100-0099/01	TAPET
	NANOTHERAPEUTICS, INC.	Compositions and Methods for Delivery of an Agent Using Attenuated Salmonella Containing Phage		U.S.	24-Aug-2000		09/645,418	Abandoned	ORD	08100-0099/00	TAPET
	NANOTHERAPEUTICS, INC.	Non-Invasive Tumor Imaging by Tumor-Targeted Bacteria		U.S.	4-Oct-2000		09/679,454	Abandoned	ORD	08100-0098/00	TAPET
		Compositions and methods for tumor-targeted delivery of effector molecules		U.S.	26-Jan-2007		11/627,743	Abandoned	CON	08100-0088/04	TAPET
		L		U.S.	20-Oct-2008		12/254,122	Abandoned	ORD	08100-0088/03	TAPET
		Ļ	18-Nov-2008	U.S.	17-Mar-2005	7452531	11/082,544	Issued	· DIV	08100-0088/02	TAPET
		_		U.S.	16-Dec-2003		10/738,423	Abandoned	DΙV	08100-0088/01	TAPET
		205 Compositions and methods for tumor-targeted delivery of effector molecules	08-Nov-2005	U.S.	24-Aug-2000	6962696	09/645,415	Issued	ORD	08100-0088/00	TAPET
	VION PHARMACEUTICALS, INC.	Compositions and methods for tumor-targeted delivery of effector molecules		Singapore		88111	200201817-4	Abandoned	88	08100-0088/00	TAPET
		Compositions and methods for tumor-largeted delivery of effector molecules		PCT	24-Aug-2000		PCT/US00/23242	Completed	ORD	08100-0088/00	TAPET
	VION PHARMACEUTICALS, INC.	05 Compositions and methods for tumor-targeted delivery of effector molecules	09-Jun-2005	New Zealand	12-Apr-2002	518354	518354	Abandoned	ORD	08100-0088/00	TAPET
		Compositions and methods for tumor-targeted delivery of effector molecules		Mexico	3-Apr-2002		PA/a/2002/003384	Abandoned	PCT	08100-0088/00	TAPET
	VION PHARMACEUTICALS, INC.	Compositions and methods for tumor-targeted delivery of effector molecules		Korea	4-Apr-2002		2002-7004371	Abandoned	PCT	08100-0088/00	TAPET
	VION PHARMACEUTICALS, INC.	Compositions and methods for tumor-targeted delivery of effector molecules		Japan	4-Apr-2002		2001-528552	Abandoned	PCT	08100-0088/00	TAPET
	VION PHARMACEUTICALS, INC.	Compositions and methods for tumor-targeted delivery of effector molecules		Israel	27-Mar-2002		148933	Abandoned	PCT	08100-0088/00	TAPET
	VION PHARMACEUTICALS, INC.	Compositions and methods for tumor-targeted delivery of effector molecules		Hong Kong	12-Nov-2003	,	3108220.2	Abandoned	PCT	08100-0088/00	TAPET
	VION PHARMACEUTICALS, INC.	Compositions and methods for tumor-largeted delivery of effector molecules		Europe	10-May-2002		957764.4	Abandoned	PCT	08100-0088/00	TAPET
	VION PHARMACEUTICALS, INC.	Compositions and methods for tumor-targeted delivery of effector molecules		China			2.0091E+11	Abandoned	DIV	08100-0088/01	TAPET
L	VION PHARMACEUTICALS, INC.	Compositions and methods for lumor-targeted delivery of effector molecules		China	4-Jun-2002		816714.1	Abandoned	PCT	08100-0088/00	TAPET
	VION PHARMACEUTICALS, INC.	Compositions and methods for tumor-targeted delivery of effector molecules		Canada	2-Apr-2002	·	2386465	Abandoned	PCT	00/8800-00180	TAPET
	VION PHARMACEUTICALS, INC.	Compositions and methods for tumor-largeted delivery of effector molecules		Brazil	4-Apr-2002		PI 00:4491-6	Abandoned	PCT	08100-0088/00	TAPET
	VION PHARMACEUTICALS, INC.	<u> </u>	23-Mar-2006	Australia	9-Apr-2002	783714	69334/00	Issued	PCT	08100-0088/00	TAPET
A		1 Process for the synthesis of anti-neoplasia agent VNP40101M	9/27/2011	U.S.	27-May-2009	8,026,095	12/454,997	Issued	ORD	08100-0095/00	TAPET
L		L		U.S.	27-Sep-2004		10/950,890	Abandoned	DIV	08100-0094/01	CLOR/ONRIGIN
L			15-Feb-2005	U.S.	13-Jun-2003	6855695	10/461,282	Issued	SR	08100-0094/00	CLOR/ONRIGIN
N	VION PHARMACEUTICALS, INC.	Water-Soluble SHPS as Novel Alkylating Agents		PCT	18-May-2004		PCT/US2004/015547	Completed	ORD	08100-0094/00	CLOR/ONRIGIN
	VION PHARMACEUTICALS, INC.			neder	12-Dec-2005		2006-533183	Abandoned	PCT	08100-0094/00	ČLOR/ONRIGIN
<u></u>	VION PHARMACEUTICALS, INC.	Water-Soluble SHPS as Novel Alkylating Agents	13-Feb-2009	Hong Kong	4-Sep-2006	HKJ1089368	6109806.9	Issued	PCT	08100-0094/00	CLOR/ONRIGIN

	Compositions and Methods for Improved Delivery and Absorption of Basic Compounds		U.S.				hactiva	8	08100-6003/01	ANCISINOR
NANOTHERAPEUTICS, INC.	Compositions and Methods for Improved Delivery and Absorption of Basic Compounds		U.S.	3-Sep-2007		60/969,672	Expired	PRO	08100-6003/00	PROVISIONAL
NANOTHERAPEUTICS, INC.	Method of collecting and analyzing air samples		U.S.	1-May-2007		60/915,316	Expired	PRO	08100-6002/00	PROVISIONAL
	METHOD OF COLLECTING AND ANALYZING HUMAN BREATH		U.S.	29-Jan-2002		60/352,322	Completed	ORD	08100-6001/00	PROVISIONAL
	METHOD OF PULSED LASER ASSISTED SURFACE		U.S.	22-Jan-2002		60/349,557	Expired	용	08100-6000/00	PROVISIONAL
	Compositions and Methods for Oral Delivery of Encapsulated 3 Aminopyrine-2-Carboxaldehyde Particles				61/948,085	PCT/US2015/018730			08100.0109-00304	
		-	U.S.				Unfiled	ORD	08100-0999/00	PROVISIONAL
***************************************	Compositions and Methoids for Oral Delivery of Encapsulated Diethylenetriaminepentaacetate Particles		Japan	19-Sep-2014		PCT/US2013/031336	Pending		08100-0103-00195	PROVISIONAL
NANOTHERAPEUTICS, INC.	Compositions and Methods for Oral Delivery of Encapsulated Diethylenethaminepentaacetate Particles					13713011.8	Pending		08100-0103/00155	PROVISIONAL
	Compositions and Methods for Oral Delivery of Encapsulated Diethylenetriaminepentaecetate Particles		Canada	14-Mar-2013		2,867,701	Pending		08100-0103/00131	PROVISIONAL
NANOTHERAPEUTICS, INC.	Compositions and Methods for Oral Delivery of Encapsulated Diethylenetriaminepentaacetate Particles		Australia	14-Mar-2013		2013235491	Pending		08100-0103/00110	PROVISIONAL
NANOTHERAPEUTICS, INC.	Compositions and Methods for Oral Delivery of Encapsulated Diethylenetriaminepentaacetate Particles		U.S.	14-Mar-2013		13/827,667	Pending	PRO	08100-0103/00000	PROVISIONAL
VION PHARMACEUTICALS, INC.	Process for high-yeild diastereoselective synthesis of dideoxynucleotides		PCT	2-Jun-1997		PCT/US1997/009486	Completed	ORD	08100-0096/00	FĎ4C
VION PHARMACEUTICALS, INC.	Process for high-yelid diastereoselective synthesis of dideoxynucleotides	21-Dec-1999	U.S.	14-Jun-1996	6005097	08/663,674	Issued	ORD PRO	08100-0096/00	FD4C
VION PHARMACEUTICALS, INC.	Process for high-yeild diastereoselective synthesis of dideoxynucleotides		Korea	11-Dec-1998		98-0710188	Abandoned	PCT	08100-0096/00	FD4C
VION PHARMACEUTICALS, INC.	Process for high-yeild diastereoselective synthesis of dideoxynucleotides		Japan	14-Dec-1998		501657/1998	Abandoned	PCT	08100-0096/00	FD4C
VION PHARMACEUTICALS, INC.	Process for high-yeild diastereoselective synthesis of dideoxynucleatides		Hong Kong	4-Jan-2000		100023.1	Abandoned	PCT	08100-0096/00	FD4C
VION PHARMACEUTICALS, INC.	Process for high-yeild diastereoselective synthesis of dideoxynucleofides		Europe	12-Jan-1999		97927916.3	Abandoned	PCT	08100-0096/00	FD4C
VION PHARMACEUTICALS, INC.	Process for high-yelid diastereoselective synthesis of dideoxynucleotides		China	14-Dec-1998		97195517.4	Abandoned	ORD	08100-0096/00	FD4C
VION PHARMACEUTICALS, INC.	Process for high-yelid diastereoselective synthesis of dideoxynucleotides		Canada	11-Dec-1998		2258160	Abandoned	PCT	08100-0096/00	FD4C
VION PHARMACEUTICALS, INC.	Process for high-yeild diastereoselective synthesis of dideoxynucleofides		Brazil	14-Dec-1998		PI 9709785-3	Abandoned	PCT	08100-0096/00	FD4C
VION PHARMACEUTICALS, INC.	Process for high-yeild diastereoselective synthesis of dideoxynucleofides	23-Mar-2000	Australia	11-Dec-1998	713764	32261/97	Abandoned	PCT	08100-0096/00	FD4C
VION PHARMACEUTICALS, INC.	Modified prodrug forms of API/AMP	01-Oct-2002	U.S.	15-Oct-2001	6458816	09/977,659	ssued	ORD	08100-0092/00	TRI
VION PHARMACEUTICALS, INC.	Modified prodrug forms of AP/AMP		Russia	12-May-2003		2003113538	Abandoned	PCT	08100-0092/00	TRI
VION PHARMACEUTICALS, INC.	Modified prodrug forms of AP/AMP		PCT	15-Oct-2001		PCT/US01/032085	Completed	ORD	08100-0092/00	TRI
VION PHARMACEUTICALS, INC.	Modified prodrug forms of AP/AMP		Mexico	10-Apr-2003		PA/a/2003-003161	Abandoned	PCT	08100-0092/00	TRI
VION PHARMACEUTICALS, INC.	Modified prodrug forms of APIAMP		Korea	11-Apr-2003		10-2003-7005178	Abandoned	PCT	08100-0092/00	TRI
VION PHARMACEUTICALS, INC.	Modified prodrug forms of AP/AMP	01-Aug-2008	Japan	15-Oct-2001	4162994	2002-533865	Issued	PCT	08100-0092/00	TRI
VION PHARMACEUTICALS, INC.	Modified prodrug forms of APIANIP	06-Jan-2006	Hong Kong	10-Feb-2004	HK1058005	4100869.4	Issued	PCT	08100-0092/00155	TRI
VION PHARMACEUTICALS, INC.	Modified prodrug forms of AP/AMP	25-May-2011	Germany	15-Oct-2001	60144706.9	1979800.8	Issued	PCT	08100-0092/00	TRI
VION PHARMACEUTICALS, INC.	Modified prodrug forms of AP/IAMP	25-May-2011	ireland	15-Oct-2001	1335726	1979800.8	issued	PCT	08100-0092/00	TR.
VION PHARMACEUTICALS, INC.	Modified prodrug forms of AP/AMP	25-May-2011	Great Britain	15-Oct-2001	1335726	1979800.8	issued	PCT	08100-0092/00	핎
VION PHARMACEUTICALS, INC.	Modified prodrug forms of AP/AMP	25-May-2011	France	15-Oct-2001	1335726	1979800.8	Issued	PCT	08100-0092/00	TRI
VION PHARMACEUTICALS, INC.	Modified prodrug forms of AP/AMP	25-May-2011	Europe	8-May-2003	1335726	1979800.8	Issued	PCT	08100-0092/00155	TRI
VION PHARMACEUTICALS, INC.	Modified prodrug forms of APIANIP	26-Oct-2005	China	4-Apr-2003	232916	1816923.6	Issued	PCT	08100-0092/00	TRI
VION PHARMACEUTICALS, INC.	Modified prodrug forms of AP/AMP	03-Jan-2012	Canada	19-Mar-2003		2423220	Issued	PCT	08100-0092/00	코
	Modified prodrug forms of AP/AMP		Brazil	11-Apr-2003		Pi0114598-3	Abandoned	PCI	08100-0092/00	코
VION PHARMACEUTICALS, INC.	Modified prodrug forms of APIAMP	13-Oct-2008	Australia	3-Mar-2011	2002211725	2002211725	Issued	PCI	08100-0092/00	TR:
	Prodrug Forms of Ribonucleotide Reductase Inhibitors 3-AP and 3-AMP	16-Jun-1998	U.S.	15-May-1997	5767134	08/856,568	issued	ORD	08100-0091/00	TR
VION PHARMACEUTICALS, INC.	Prodrug Forms of Ribonucleotide Reductase Inhibitors 3-AP and 3-AMP	27-Feb-2003	Russia	14-Dec-1999	2199531	99127343	Abandoned	PCT	08100-0091/00	TRI
VION PHARMACEUTICALS, INC.	Prodrug Forms of Ribonucleotide Reductase Inhibitors 3-AP and 3-AMP		PCT	14-May-1998		PCT/US98/009750	Completed	ORD	08100-0091/00	TRI
	Prodrug Forms of Ribonucleotide Reductase Inhibitors 3-AP and 3-AMP		Korea	15-Nov-1999		1999-7010565	Abandoned	PCT	08100-0091/00	TRI
VION PHARMACEUTICALS, INC.	Prodrug Forms of Ribonucleotide Reductase Inhibitors 3-AP and 3-AMP		Japan	11-Nov-1999		10-549484	Abandoned	PCT	08100-0091/00	าล
VION PHARMACEUTICALS, INC.	Prodrug Forms of Ribonucleotide Reductase inhibitors 3-AP and 3-AMP		Hong Kong	29-Jul-2000		104764.6	Abandoned	ORD	08100-0091/00	ĪŖ
VION PHARMACEUTICALS, INC.	Prodrug Forms of Ribonucleotide Reductase Inhibitors 3-AP and 3-AMP		Europe	14-May-1998	EP0988285	9892247.6	Abandoned	ORD .	08100-0091/00	īRI
		25.000	o mind	1,1100						

NANOTHERAPEUTICS, INC	Methods of Treatment of C. Difficile Spores With Ramoplanin	u.s.	16-Apr-2014	61/980,370	Pending	PRO	08100.6031/00000	PROVISIONAL
NANOTHERAPEUTICS, INC	Compositions and Methods for Oral Delivery of Encapsulated 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone Particles	U.S.	5-Mar-2014	61/948,085	Pending	PRO	08100.6030/00000	PROVISIONAL
	Compositions and Methods for O-Acetylated High-Molecular-Weight Polygatectionic Acid Typhoid Vaccine	U.S.				PRO	8100-6029/00000	PROVISIONAL
	Compositions and Methods for Oral Delivery of Encapsulated Diethlenetriaminepentaacetate Particles	u.s.	3-Mar-2013	61/771,873	Abandoned	PRO	08100-6028/00	PROVISIONAL
The state of the s	Compositions and Methods for Oral Delivery of Encapsulated Diethlenetraminepentagodate Particles	U.S.	22-Mar-2012	61/614,333	Expired	PRO	08100-6027/00	PROVISIONAL
	Methods for Treating Cancer by Administering Tumor-Targeted Bacteria and an Immunomondulatory Agent	1777	28-Jan-2002	60/352,259	Completed	PRO	08100-6026/00	PROVISIONAL
	Compositions and Methods for Delivery of an Agent Using Attenuated Solmonella Containing Phage	U.S.	26-Aug-1999	60/150,928	Completed	PRO .	08100-6025/00	PROVISIONAL
VION PHARMACEUTICALS, INC.	Non-Invasive Tumor Imaging by Tumor-Targeted Bacteria	U.S.	4-Oct-1999	60/157,620	Completed	PRO	08100-6024/00	PROVISIONAL
National Control of the Control of t	Hypoxia-selective agents as anti-cancer agents	U.S.	12-Apr-2005	60/670,308	· Completed	PRO	08100-6023/00	PROVISIONAL
	Phosphate-bearing prodrugs of sulfonyl hydrazines as hypoxia-selective antineoplastic agents	U.S.	6-Oct-2004	60/616,500	Completed	PRO	08100-6022/02	PROVISIONAL
		U.S.	1-Oct-2004	60/615,419	Completed	PRO	08100-6022/01	PROVISIONAL
		U.S.	21-Sep-2004	60/611,623	Completed	PRO	08100-6022/00	PROVISIONAL
		U.S.	14-Mar-2007	60/906,896	Completed	PRO	08100-6021/04	PROVISIONAL
		U.S.	13-Mar-2006	60/781,866	Completed	PRO	08100-6021/03	PROVISIONAL
		U.S.	10-Mar-2005	60/660,356	Completed	PRO	08100-6021/02	PROVISIONAL
	Novel Hydrazone and Imine Compounds as Anti-Cancer Agents	U.S.	10-Mar-2005	60/660,357	Completed	PRO	08100-6021/01	PROVISIONAL
		U.S.	3-Mar-2004	60/549,598	Completed	PRO	08100-6021/00	PROVISIONAL
The state of the s	A CONTRACTOR OF THE PROPERTY O	U.S.	10-Mar-2004	60/551,981	Completed	용	08100-6020/01	PROVISIONAL
	Method of treating ischemia, reperfusion, myocardial infaration and other cardiovascular conditions and disease states	U.S.	4-Mar-2004	60/549,950	Completed	PRO	08100-6020/00	PROVISIONAL
- Land Control of the		U.S.	27-May-2008	61/128,975	Completed	RO	08100-6019/01	PROVISIONAL
The state of the s	Methods of Synthesizing VNP4010M	U.S.	24-May-2007	60/931,528	Completed	용	08100-6019/00	PROVISIONAL
	Modified Prodrug forms of AP/AMP	U.S.	13-Oct-2000	60/240,529	Completed	PRO	08100-6018/00	PROVISIONAL
		U.S.	4-Oct-1999	60/157,637	Completed	PRO	08100-6017/02	PROVISIONAL
		U.S.	4-Oct-1999	60/157,581	Completed	PRO	08100-6017/01	PROVISIONAL
	Composition and Method for the Tumor-Targeted Delivery of Anti-Angiogenic Factors	U.S.	4-Oct-1999	60/157,500	Completed	용	08100-6017/00	PROVISIONAL
		U.S.	18-Mar-2005	60/663,454	Completed	PRO	08100-6016/01	PROVISIONAL
	Alkyliguanyltransferase Assays	U.S.	11-Mar-2005	60/660,738	Completed	PRO	08100-6016/00	PROVISIONAL
NANOTHERAPEUTICS, INC.	Compositions and Methods for Oral Delivery of Encapsulated Diethylenetriaminepentascetate Particles	U.S.	10-Aug-2010	61/372,184	Pending	PRO	08100-6015/00	PROVISIONAL
The state of the s	Use of Ramoplanin to Treat Diseases Associated with the Use of Antibiotics	U.S.	12-May-2003	60/469,803	Completed	PRO	08100-6014/00	PROVISIONAL
	Method for Preventing Gram-Positive Bacteremias	U.S.	6-Sep-2002	60/408,596	Completed	PRO	08100-6013/00	PROVISIONAL
	Method For Reducing Transmission of Nosocomial Pathogens in a Health Care Facility	U.S.	23-Apr-2003	60/465,757	Completed	PRO	08100-6012/00	PROVISIONAL
	Purification of Influenza Viral Antigens	U.S.	12-Dec-2006	60/874,354	Expired	PRO	08100-6011/00	PROVISIONAL
CARRINGTON LABORATORIES, INC.	Nasal Powder Vaccine Compositions and Uses Thereof	U.S.	24-May-2004	60/573,790	Expired	PRO	08100-6010/00	PROVISIONAL
NANOTHERAPEUTICS, INC.	Bicyclic Compounds and Methods of Making and Using Same	U.S.	3-Dec-2008	61/119,538	Pending	PRO	08100-6009/00	PROVISIONAL
NANOTHERAPEUTICS, INC.	5-HTS Modulating compounds and uses thereof	U.S.	17-Nov-2005	60/738,084	Completed	PRO	08100-6008/00	PROVISIONAL
NANOTHERAPEUTICS, INC.	Thenopyridinone compounds and methods of treatment	U.S.	17-May-2004	60/571,852	Completed	PRO	08100-6007/00	PROVISIONAL
NANOTHERAPEUTICS, INC.	Process of Modifying Particles Using Filtration and Compositions Produced Thereby	U.S.	26-Oct-2008	61/108,518	Inactive	PRO	08100-6006/00	PROVISIONAL
	Topical Hydrogel Composition	U.S.	18-Aug-2008	61/089,568	Pending	PRO	08100-6005/00	PROVISIONAL
	1 The state of the	C.S.	/002-40M1+7	000000000	EVPHEN	770	00100 00100	- NO MICHOLES

RECORDED: 03/20/2015 REEL: 035236 FRAME: 0957